The sensitivity of glutamate transport to the depletion of glutathione by Seib, Todd M.
University of Montana 
ScholarWorks at University of Montana 
Graduate Student Theses, Dissertations, & 
Professional Papers Graduate School 
2004 
The sensitivity of glutamate transport to the depletion of 
glutathione 
Todd M. Seib 
The University of Montana 
Follow this and additional works at: https://scholarworks.umt.edu/etd 
Let us know how access to this document benefits you. 
Recommended Citation 
Seib, Todd M., "The sensitivity of glutamate transport to the depletion of glutathione" (2004). Graduate 
Student Theses, Dissertations, & Professional Papers. 6637. 
https://scholarworks.umt.edu/etd/6637 
This Thesis is brought to you for free and open access by the Graduate School at ScholarWorks at University of 
Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an 
authorized administrator of ScholarWorks at University of Montana. For more information, please contact 
scholarworks@mso.umt.edu. 
Maureen and Mike 
MANSFIELD LIBRARY
The University of
Montana
Permission is granted by the author to reproduce this material in its entirety, 
provided that this material is used for scholarly purposes and is properly 
cited in published works and reports.
**Please check "Yes" or "No" and provide signature
Yes, I grant permission
No, I do not grant penmssion
Author’s Signature:
Date:
Any copying for commercial purposes or financial gain may be undertaken 
only with the author’s explicit consent.
8/98

THE SENSITIVITY OF GLUTAMATE TRANSPORT TO THE DEPLETION OF
GLUTATHIONE
Todd M. Seib 
B.S., Biochemistry, Duquesne University 
Submitted in partial fulfillment of the requirements for the 
Degree of Master of Science 
Division of Biological Sciences 
The University of Montana 
2004
Approved by:
Chairpersoi
dvisorearl
Dean, Graduate School
8 * S o - 0 4
Date
UMI Number: EP37438
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
UMT
0»Mrt«tion PuMiahmg
UMI EP37438
Published by ProQuest LLC (2013). Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code
ProQuesf
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106 -1346
Todd M. Seib, M.S., 2004 Biochemistry
Glutamate Transporter Sensitivity to Glutathione Depletion and Reactive Oxygen Species 
Chairperson: Ralph Judd Ph.D.
Abstract
The amino acid glutamate is known to mediate both excitatory synaptic signaling and 
receptor-mediated excitotoxicity in the mammalian CNS. Excitotoxic insults produced by 
excessive levels of glutamate are thought to trigger a number of deleterious pathways, 
including ion-induced osmotic swelling, Ca^  ̂-mediated pathology, and the production of 
reactive oxygen species (ROS). Therefore, the efficient regulation of glutamate in the 
extracellular environment by neuronal and glial glutamate transporters is fundamental to 
the prevention of neuronal injury and neurodegeneration. Previous studies have shown 
that excitatory amino acid transporters (EAATs) are sensitive to oxidative inactivation by 
exogenous ROS. The vulnerability of these transporters may represent an important link 
between the pathological processes of excitotoxicity and oxidative stress. In the present 
study, the sensitivity of glutamate transport to mild oxidative stress induced by chronic 
glutathione depletion was examined in long-term cultures of primary astrocytes. 
Pharmacology and immunoblotting experiments indicated that the EAAT expressed in 
the astrocyte cultures was the GLAST subtype. To assess the sensitivity of the EAATs to 
endogenous levels of ROS produced under normal conditions, intracellular GSH was 
depleted with buthionine sulfoximine (ESC) and the rate of D-aspartate transport 
measured. GLAST activity did not change in the astrocytes chronically depleted of GSH, 
suggesting that GLAST was insensitive to oxidative inactivation under these conditions. 
The sensitivity of transport activity was then examined by exposing cells to a non-lethal 
level of exogenous oxidants. While transport activity decreased following the mild 
oxidant challenge, there was not a significant potentiation of this effect in cells treated 
with BSO. Tryptophan fluorescence was also measured as a marker of oxidative damage 
to protein, although, neither chronic GSH-depletion nor the acute mild ROS treatment 
produced a significant change. This suggested that under the conditions used, loss of 
transport activity may be a more sensitive indicator of oxidative stress than more general 
markers of protein oxidation. We conclude that while glutamate transport is sensitive to 
oxidative stress, GSH may not be important for protection from ROS. The relationship 
between other antioxidant systems and glutamate transport activity requires further 
investigation to more fully understand the pathological mechanisms involved in EAAT 
dysfunction.
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Introduction
The research presented in this thesis investigates the vulnerability of the glutamate 
transporters in the central nervous system (CNS) to oxidative damage and the role that 
glutathione may play as an oxidative protectant. As will be discussed, the glutamate 
transporters play a critical role in regulating extracellular glutamate levels in the brain 
and an attenuation of their activity by oxidative stress could increase the likelihood of 
glutamate mediated neuropathology. Therefore, the sensitivity of the glutamate 
transporters may represent a significant link between two major pathological pathways 
known to contribute to brain damage: glutamate-mediated neurodegeneration 
(excitotoxicity) and free-radical-mediated oxidative damage. For this reason, the 
introduction to this thesis will review: i) glutamate as an excitatory neurotransmitter, its 
role in excitotoxicity, and its regulation by the glutamate transporters ii) reactive oxygen 
species formation and oxidative stress, the susceptibility of the CNS, and protective 
mechanisms, and Hi) the potential link glutamate transport plays between excitotoxicity 
and oxidative stress.
G l u t a m a t e  a s  a n  E x c it a t o r y  N e u r o t r a n s m it t e r
Glutamate is now widely accepted as the major excitatory neurotransmitter in the 
mammalian CNS and is thought to be responsible for most fast synaptic transmission, as 
well as contribute to developmental plasticity, and higher cognitive function (memory, 
learning) (Cotman et al., 1995). The nature of glutamate’s excitatory action on brain 
tissue was first confirmed in 1954 by Hayashi, and since then, interest in glutamate
neurotransmission has continued to grow and intensify as accumulating evidence 
suggests its role not only in normal synaptic communication, but also in the development 
of neurodegenerative disease (e.g. ALS, Parkinson’s, Alzheimer’s), traumatic neuronal 
injury damage, tumor development, and infectious disease (e.g. HIV) (Lipton et al., 1994; 
for review see Danbolt, 2001). However, glutamate is not a newly discovered molecule, 
even though its role as a neurotransmitter may be. Glutamate is an amino acid, acting as a 
metabolite in various cellular reactions (e.g. protein synthesis, glutamine synthesis, 
glutathione synthesis, and energy metabolism). Glutamate is also highly distributed 
throughout the CNS. These features are not common to other well-characterized 
neurotransmitters (GABA, dopamine, seratonin, norepinephrine, etc.) and therefore 
glutamate’s role as a neurotransmitter was initially questioned. Over a period of about 
thirty years studies have established that glutamate exhibits all the necessary hallmarks of 
a classical neurotransmitter: (1) glutamate exists in the tissues of the CNS at a 
concentration of about 5-15 mmol per kg wet weight depending on the region 
(Schousboe, 1981), (2) exogenously applied glutamate has the ability to activate post- 
synaptic receptors in a manner similar to that of endogenous transmitter, (3) it is 
sequestered into synaptic vesicles via an energy dependent mechanism driven by an 
electrochemical proton gradient and (4) released in a Ca^  ̂dependent manner upon 
depolarization of pre-synaptic membrane(for review see Ozkan et al., 1998), and finally 
(5) a mechanism to terminate signal transmission exists (i.e. transport) (for review see 
Danbolt, 2001).
E x c it a t o r y  A m in o  A c id  R e c e p t o r s
When an action potential propagates down the axon of a glutamatergic neuron, Ca^  ̂entry 
through voltage-gated calcium channels stimulates the fusion of glutamate-containing 
synaptic vesicles, and glutamate is released into the synaptic cleft. Upon release, 
glutamate can potentially bind to a number of receptors, including post-synaptic ion- 
coupled receptors, the activation of which allows the excitatory signal to continue. 
Glutamate receptors can be divided into two main subtypes, ionotropic and metabotropic.
The ionotropic receptors, which are located pre and post-synaptically, bind 
glutamate and induce post-synaptic depolarization by gating voltage-dependent and 
voltage-independent currents carried by Na^, and Ca^  ̂(for review see Monaghan et 
al., 1989). The three subtypes of ionotropic receptors are pharmacologically distinct and 
were initially characterized by and named after specific agonists (N-methyl-D-aspartate, 
NMDA; kainic acid, KA; and a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid, 
AMP A). The NMDA receptor is both ligand and voltage gated, allowing Ca^^and Na^ 
influx through its channel. Aside from the binding site for L-glutamate, there are at least 
four other pharmacologically distinct binding domains on the receptor. Among them are: 
1) a glycine binding site, 2) a site within the channel that binds phenylcyclidine and 
related compounds, 3) a voltage-dependent Mg^  ̂binding site, and 4) an inhibitory site 
that binds Zn^  ̂and other divalent cations. At the resting potential, the binding of Mg^  ̂
within the NMDA receptor channel effectively blocks the receptor. The influx of Ca^  ̂
through the NMDA receptor can occur only after membrane depolarization (often by Na^ 
influx through the non-NMDA ionotropic receptors) relieves the Mĝ '̂  blockade.
Ca^^-influx through NMDA is linked to a number of downstream signaling 
pathways including PLAj activation, the production of reactive oxygen species, cGMP 
activation, and phosphorylation of transcription factors (Farooqui et al., 1994). Through 
these and other yet undefined post-synaptic mechanisms, NMDA receptors are thought to 
contribute significantly to plasticity in the developing and mature brain. NMDA receptor 
activation is the pivotal event in the recruitment of additional receptors and the 
amplification of post-synaptic signal in the process of long-term potentiation (LTP) 
(Monaghan et al., 1989). LTP is characterized by increases in post-synaptic potentials 
following high-frequency afferent stimulation of a discrete circuit (Collingridge et al., 
1987). The post-synaptic events in LTP are particularly noteworthy, however, in that 
synaptic transmission within the stimulated circuit is enhanced over the long term 
(minutes to days), representing the first potential molecular mechanism underlying 
learning and memory.
The second receptor subtype, the metabotropic receptors (mGluRs), are located 
both pre- and post -synaptically and act as G-protein coupled receptors linked to 
phospholipase C activation and both activation and inhibition of the adenylate cyclase. At 
least six different subtypes of mGluRs have been identified and are classified into three 
subgroups based on sequence and pharmacology (Cotman et al., 1995). The continued 
development of conformationally constrained glutamate analogs ( 1 -aminocyclopentane- 
trans-1, 3-dicarboxylate, trans-ACPD; and 2-amino-4-phosphonobutyrate, AP4) that are 
inactive at the ionotropic receptors and exhibit pharmacologically distinct activity 
between the subgroups, can serve as tools to further differentiate mGLuR subtypes.
E x c it o t o x ic it y
A shared mechanism exists through which normal function and toxicity can occur in 
glutamate neurotransmission. This mechanism is primarily mediated by the ionotropic 
receptors. As previously mentioned, glutamate stimulates ionotropic receptors as a 
necessary part of normal signal transmission. Paradoxically, the ionotropic receptor 
subtype also mediates the process through which endogenous glutamate can be toxic. 
Excitotoxicity is a process whereby excessive levels of glutamate can over stimulate the 
ionotropic receptors leading to osmotic swelling, influx, and production of reactive 
oxygen intermediates, which can eventually result in neuronal cell death (Choi, 1988; 
Dugan et al., 1994; Farooqui et al., 1994; Lipton et al., 1994; Zeevalk et al., 1998). 
Currently, it is accepted that there are two main mechanisms of neuronal damage 
associated with excessive depolarization from high glutamate concentrations; osmotic 
damage from ion-gradients, and Câ '" related damage (Choi, 1985; Choi, 1987).
The first mechanism, and the most acute, is caused by the influx of Na^ ions 
through ionotropic receptors following depolarization. Consequentially, Cl ions enter the 
cell to restore charge equilibrium and water influx occurs as the cell becomes hypertonic. 
Additionally, increased ATP consumption from activated NaVK* ATPases may occur in 
response to increased Na* permeability. Eventually, neuronal swelling results, leading to 
cell death. This mechanism is dependent upon extracellular Cl and Na"̂  ion availability, 
can be mimicked by high amounts of K*, and may be less significant in vivo than in in 
vitro preparations (Choi, 1987). A second, more chronic component of glutamate 
neurotoxicity is observed and shown to be Ca^^-dependent (Choi, 1987).
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Figure 1. The glutamatergic synapse. Intracellular glutamate in the pre-synaptic 
terminal is sequestered into vesicles through the vesicular glutamate transporter (GVT), 
Following membrane depolarization voltage-dependent calcium channels open and Ca^  ̂
influx stimulates the fusion of glutamatergic vesicles with the membrane. The release of 
glutamate into the extracellular space results and through receptor-mediated 
depolarization, the excitatory signal continues. Both ionotropic and metabotropic 
excitotory amino acid receptors are identified pharmacologically with selective agonists 
(i.e. NMDA, N-methyl-D-aspartate; KA, kainic acid; and AMP A, a-amino-3-hydroxy-5- 
methyl-4-isoxazole propionic acid; ACPD 1 -aminocyclopentane-trans-1, 3- 
dicarboxylate). The EAATs (acronym for excitatory amino acid transporter cloned from 
human) are Na+-dependent high-affinity transport proteins that remove glutamate from 
the extracellular space and serve to terminate the excitatory signal. System Xq- 
(xCT/4F2hc) exchanges extracellular cystine for intracellular glutamate.
Not surprisingly, the NMDA receptor became an attractive candidate as the primary 
mediator of the Ca^* dependent component of glutamate neurotoxicity (for review see 
Choi, 1988). The initial observation that Ca^^-free conditions were neuroprotective for 
neurons exposed to toxic amounts of glutamate (0.5mM) tied Ca^  ̂to glutamate, a 
requisite beginning for NMDA involvement (Choi, 1985; Choi, 1987). More convincing 
evidence came, however, when investigators demonstrated that Mg^  ̂(known to serve as a 
voltage block to NMDA receptors) was also capable of blocking the late Ca^  ̂effect 
(Choi, 1987). To support these findings, Murphy and colleagues demonstrated that 
NMDA induced increases in intracellular Ca^  ̂levels, a process that was both sensitive to 
Mg^  ̂and insensitive to La^  ̂and Li* (Murphy et al., 1987). This finding suggests that 
increases in intracellular Ca^  ̂are mediated primarily by influx through the NMDA 
receptor and less significantly through voltage-gated channels activated by membrane 
depolarization. Pharmacological studies then provided strong evidence for NMDA 
involvement in excitotoxicity when investigators found that selective NMDA antagonists 
(2-amino-5-phosphonovalerate, ketamine, APH) effectively attenuated glutamate 
neurotoxicity, while non-NMDA antagonists had less effect (Choi et al., 1988).
It is now accepted that increased calcium influx through the NMDA receptor is 
the second (and longer-term) consequence of glutamate-induced excitotoxicity. The 
implications of this statement can be profound. Under normal circumstances, intracellular 
Ca^  ̂acts beneficially as a second messenger. However, sustained increases in 
intracellular Ca^  ̂can over-activate enzyme systems (e.g. phospholipase Aj, neuronal 
NOS, proteases, and calcium/calmodulin complexes) which can lead to impairment of 
mitochondrial oxidative phosphorylation, depletion of energy reserves, reactive oxygen
species formation, and proteolysis (Choi, 1988; Dugan et al., 1994; Ciani et al., 1996; 
Leist et al., 1997; Halliwell, 2001). The conclusion is that excitotoxicity arises from 
endogenous stores of glutamate and is mediated through the identical mechanism as 
normal neurotransmission, namely, EAA receptor activation. Clearly, one of the most 
significant threats to the CNS is that which lies within, as neurodegeneration is the 
endpoint for glutamate-induced excitotoxicity (Choi, 1988).
The excitotoxic potential of glutamate, accompanied with it’s high levels in the 
CNS, has made it a prime candidate in a number of pathologies, including acute damage 
in stroke, anoxia, and trauma as well as chronic neurodegenerative diseases such as 
amyotrophic lateral sclerosis, Alzheimer’s, and Parkinson’s disease. It follows then that 
the efficient regulation and removal of glutamate from the synaptic cleft is required to 
insure the delicate balance between normal neurotransmission and neuropathology. While 
more than one protein family has the ability to transport glutamate, it is generally 
accepted that the majority of glutamate regulation in the CNS occurs through the action 
of high affinity, sodium-dependant, excitatory amino acid transporters (EAATs) 
(Robinson et al., 1997).
L-GLUTAMATE TRANSPORT
Within milliseconds following release from the presynaptic nerve terminal into the 
synaptic cleft, glutamate is moved intracellularly through the glutamate transporters 
(Clements et al., 1992). The efficient removal of L-glutamate occurs continuously and 
establishes an intracellular store of glutamate several thousand fold higher than that in the 
extracellular space (depending on region the brain contains 5-15 mM per kg wet weight
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Figure 2. Na-dependent excitatory amino acid transport.
but only 3-10 (xM is found extracellularly) (for review see Danbolt, 2001). The transport 
of glutamate is thermodynamically unfavorable and occurs via secondary active 
transport. The energy barrier of glutamate transport is overcome by coupling it with the 
exergonic flow of sodium into and potassium out of the cell down their chemical and 
electrical gradients originally established by a NaVK^ ATPase. Inhibition of NaVK^ 
ATPase with ouabain uncouples ATP driven flow of sodium and potassium against their 
gradients and as a result their exergonic flow back down their gradients can no longer be 
harnessed for secondary active transport and glutamate uptake decreases (and may 
possibly reverse) (Volterra et al., 1994). The stoichiometry of glutamate transport 
(Figure 2) is believed to involve the co-transport of three sodium ions and a proton in 
exchange for one potassium ion for each molecule of glutamate transported (at 
physiological pH L-glutamate has a net negative charge) resulting in an electrogenic 
process (net positive charge transported) (Zerangue et al., 1996). A non-thermodynamic 
chloride conductance is thought to be associated with transport as well (Fairman et al., 
1995).
Following transport into neurons and glia, glutamate is subject to metabolic 
reactions, the most important of which are catalyzed by L-glutamate decarboxylase 
(GAD), glutamic-oxaloacetic transaminase (GOT), glutamate dehydrogenase (GLDH), 
glutamine synthetase, and glutaminase. The two most common fates of glutamate are (1) 
conversion to glutamine by glutamine synthetase (following transport into glial cells) and 
(2) conversion to a-ketoglutarate through the actions of GLDH or GOT. Glutamine can 
be transported from astrocytes into neurons and then converted back to glutamate for 
synaptic release. This process, known at the glutamine-glutamate cycle, allows
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glutamine to contribute to glutamate recycling by serving as a non-excitotoxic precursor 
(does not bind to glutamate ionotropic receptors) and acts as a secondary intracellular 
glutamate pool (Schousboe, 1981; Danbolt, 2001). a-Ketoglutarate can enter oxidative 
metabolism through the TCA cycle or be converted back to glutamate through 
aminotransferases or by GLDH catalyzed reactions running in reverse.
Just as the glutamate-initiated excitatory signal is mediated through a number of 
receptors, the process of signal termination is dependent upon multiple proteins. In 1992 
the existence of multiple glutamate transporters was confirmed with the isolation of 
cDNA clones from rat brain (GLT-1 and GLAST) and rabbit intestine (EAACl) (for 
review see Robinson et al., 1997). Antibodies raised against the C-terminal domains of 
each transporter detect 65-73 kDa proteins in immunoblots and have been used to 
identify the cellular distribution of the transporters in rat CNS (Rothstein et al., 1994). 
GLT-1 and GLAST are responsible for the majority of activity attributed to the glutamate 
transporters in the mammalian CNS (Robinson et al., 1997; Danbolt, 2001). Of the 
known subtypes, GLT-1 is the most predominant transporter throughout the brain and is 
primarily expressed on astrocytes in the normal adult rat CNS. Neuronal expression of 
GLT-1 is thought to be restricted to neurons of the retina even though GLT-1 mRNA has 
been found in certain populations of neurons. The regional distribution of GLAST is less 
widespread than GLT-1, however in the cerebellum it is the major glutamate transporter. 
Unlike GLT-1, GLAST protein and mRNA appear to be exclusively localized to glia.
The concentration of EAACl in the brain is lower than GLAST and GLT-1 and thus 
information on EAACl localization is less well known. It is generally agreed that 
EAACl has a wide neuronal distribution in the mammalian brain in both glutamatergic
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and GABAergic neurons with the highest levels of EAACl protein expressed in the 
hippocampus, cerebellum, and basal ganglia (for review see Danbolt, 2001).
Five sodium-dependent glutamate transporters have been identified and cloned in 
the human CNS and have been named excitatory amino acid transporters 1-5 (EAATl, 
EAAT2, EAAT3, EAAT4 and EAATS) (for reviews see Rothstein et al., 1994; Danbolt, 
2(X)1). Based on sequence homology, EAAT I is the human homolog of GLAST, EAAT2 
is the homolog of GLT-1, and EAATS is homologous to EAACl. Among the subtypes, 
it is accepted that L-glutamate, L-aspartate, and D-aspartate serve as substrates (Arriza et 
al., 1994; Robinson et al., 1997). Transport-mediated current measurements, radiolabeled 
uptake, and inhibition studies now indicate that cysteine can also serve as a substrate for 
the glutamate transporters (predominantly EAATS) (Zerangue et al., 1996; Chen et al., 
200S).
The exact topology of the glutamate transporters is not currently agreed upon and 
further delineation is necessary. A consensus exists, however, that common to the 
subtypes are at least six cc-helical transmembrane domains with a long extracellular 
stretch between TMS and TM4 and that both the N- and C-terminals are intracellular 
(Danbolt, 2001). The glutamate transporters, apart from regional, cellular, and subtype 
distinctions, exhibit yet another level of complexity. Freeze-fracture electron microscopy 
and electrophysiological studies in oocytes now indicate that the glutamate transporters 
may also function as oligomers, consisting of as many as five symmetrical domains 
(Eskandari et al., 2000).
The EAATs and their homologues are not the only proteins capable of 
translocating glutamate across the plasma membrane in the mammalian CNS. Bannai first
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described a transporter that mediated a one-to-one exchange mechanism for glutamate 
and cystine in fibroblasts, now referred to as system X^- (Bannai, 1986). Unlike the 
EAATs, this exchange process is Na^-independent and under normal conditions 
transports glutamate out of the cell, rather than sequestering it intracellularly. Bannai 
demonstrated that glutamate and cystine can serve as substrates for exchange of 
themselves or the other on both sides of the membrane (Bannai, 1986). Despite the 
competitive nature of exchange, the intracellular glutamate levels are much higher than 
cystine and dictate that the system exchanges an intracellular glutamate for an 
extracellular cystine under normal physiological conditions (Bannai, 1986; Cho et al., 
1990).
T h e  P r e s e n c e  o f  R e a c t iv e  O x y g e n  S p e c ie s
The fidelity of glutamate transport can be compromised through a number of pathological 
mechanisms, potentially resulting in excessive glutamate levels and excitotoxicity. The 
production of ROS is one mechanism that may adversely affect glutamate transport. 
Reactive oxygen species include free radicals and reactive non-radicals. Free radicals are 
species containing one or more unpaired electrons. A broad range of compounds fall 
under this definition, including superoxide radical (Og* ), hydroxyl radical (•OH), and 
nitric oxide (NO*). Technically, molecular oxygen (O2 ) could be included as well due to 
the two unpaired electrons in the 2p orbital. Reactive non-radicals include hydrogen 
peroxide (H2 O2 ), peroxynitrite (ONOO ), and singlet oxygen (‘O2 ). ROS are generally 
very reactive and can easily abstract hydrogen atoms and electrons from important 
macromolecules (proteins, lipids, carbohydrates).
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A major source of ROS in respiring cells can be attributed to the incomplete 
reduction of molecular oxygen by mitochondrial cytochrome oxidase enzymes (Figure 3). 
As a consequence, ROS are continuously generated, and, depending upon the type and 
amount of species formed, the effects can be both deleterious and beneficial to the cell 
(Halliwell, 1992; Juurlink et al., 1998; Halliwell, 2001).
One of the most common ROS formed during normal mitochondrial respiration is 
a diatomic oxygen molecule containing an unpaired electron known as superoxide anion 
(O2 * ). Outside of electron transport, superoxide can be produced through a number of 
ways, including arachidonic acid metabolism, phagocytic generation (monocytes, 
neutrophils, eosinophils, macrophages), and autooxidation of cysteine and 
catecholamines (Juurlink et al., 1998).
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Figure 3. The production of reactive oxygen species.
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Once formed, superoxide has the ability to react with cellular constituents (particularly 
proteins containing thiol groups and membrane lipids), as well as with other radicals such 
as NO*. The consequences of superoxide formation are often destructive, a desirable 
attribute when used by phagocytes to defend healthy cells from foreign organisms. 
However, not all pools of superoxide are damaging. Cell signaling processes and growth 
regulation are mediated by the release of superoxide from a variety of cell types 
(Halliwell, 1992). A scavenging mechanism exists to limit cellular exposure to 
superoxide anion whereby a superoxide dismutase (SOD) enzyme (Cu, Zn-SOD, Mn- 
SOD) converts superoxide to hydrogen peroxide and molecular oxygen.
Superoxide dismutation is the primary source of hydrogen peroxide (H2 O2 ). 
Because H2 O2  contains no unpaired electrons, it does not qualify as a free radical 
(Halliwell, 1992). The potential destructive nature of H2 O2  lies in its ability to cross cell 
membranes easily and react with the transition metals, like iron. For example, through the 
Fenton reaction, H2 O2  oxidizes iron (II) ion (Fe^*) to iron (III) ion (Fe^^) and the hydroxyl 
radical (*OH) and hydroxy ion are formed. The effects of hydroxyl radical formation are 
often severe. Hydroxyl radicals react with most macromolecules through the abstraction 
of an electron, inducing DNA strand breakage at the deoxyribose end of the nitrogenous 
bases, lipid peroxidation by abstracting a hydrogen atom from polyunsaturated fatty acid 
side chains, and enzyme inactivation through oxidation of protein thiol groups (often 
involving enzymes such as GSH peroxidase and GSH reductase that serve to buffer 
intracellular oxidants) (Juurlink et al., 1998; Halliwell, 2001).
Nitric oxide (NO*) is yet another deleterious mediator of oxidative stress. Nitric 
oxide reacts with O2 * to yield ONOO, which can deliver a direct oxidative insult or can
16
decompose to form the more harmful *OH (Radi et al., 1991). Additionally, NO* 
inhibits cytochrome oxidase (complex IV) activity, thereby limiting oxygen consumption 
in respiring cells.
T h e  CNS i s  S u s c e p t i b l e  t o  O x i d a t i v e  D a m a g e
Two main features of the CNS make it especially vulnerable to oxidative damage; (1) the 
capacity for reactive oxygen species (ROS) production is great, owing in part to the high 
metabolic demands of the CNS and (2) the neuronal specialization present in the CNS is 
membrane based, the primary components of which (lipids and proteins) are targets of 
oxidative damage.
The ATP requirements of the CNS are high and can be attributed to the 
establishment of membrane potentials, storage and release of neurotransmitter, and the 
synthesis of metabolites for normal function. The particularly high-energy needs of the 
CNS are coupled to 20% of the basal 0% consumption and thus incomplete mitochondrial 
reduction of O2 can be a significant source of ROS such as superoxide (for review see 
Halliwell, 1992). Other sources of ROS in the CNS, such as the autooxidation of 
dopamine and microglial activity (producing H2O2  and superoxide), compound the stress 
generated through aerobic respiration. The pathological threat posed by the presence of 
peroxides is heightened by the transition metal enrichment of the CNS where the reaction 
with iron may lead to *OH production. In conditions where brain injury occurs, 
especially in developing brains, the presence of neuronal NOS is known to play a major 
role in advancing the damage initiated by hypoxia (Black et al., 1995; Ferriero et ai., 
1996; Muramatsu et al., 2000). The heightened risk for ROS damage is furthered by an
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unfavorable antioxidant environment. While ascorbate is generally perceived as a 
prominent antioxidant, the high concentrations of ascorbate in the gray and white matter 
of the CNS can have a pro-oxidant function (dependent upon the presence of iron or 
copper). Additionally, the activities of certain antioxidants (catalase) are low in the CNS 
and may contribute to higher than normal ROS damage.
Nervous system function is highly membrane based. The proximity of numerous 
neuronal membranes coupled with the potential for synaptic diffusion of transmitters 
requires selective regulation at the membrane level. The all-or-nothing generation of 
action potentials is a function unique to neurons and by design relies on proper membrane 
depolarization. Membrane ion channel proteins mediate depolarization and 
hyperpolarization primarily through passive and gated transport of Na* and K .̂ Pre- and 
post-synaptic membrane receptors regulate the type (excitatory or inhibitory) and 
intensity of signal that is received by post-synaptic neurons following transmitter release. 
Enzymatic and transport processes that serve to terminate the signal are also mediated at 
the membrane level. Synaptic transmission, from the establishment of an action potential 
to termination of the signal is highly dependent on membrane function and integrity.
The lipid and protein components of the cellular membranes are primarily 
responsible for maintaining membrane integrity and mediating cellular function. Cells of 
the CNS have a distinct lipid composition that is rich in polyunsaturated fatty acids 
(docosahexaenoic acid C22:6), which are susceptible to radical attack leading to a 
destructive cascade of lipid peroxidation reactions. Lipid peroxidation is one of the most 
damaging consequences of hydroxyl radical production in the CNS (for reviews see 
Juurlink et al., 1998; Halliwell, 2001). The first step in lipid peroxidation is abstraction of
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a hydrogen atom from a methylene carbon by hydroxyl radical. A lipid radical results, 
which gives rise to a peroxyl radical when combined with oxygen. The peroxyl radical is 
converted to a lipid hydroperoxide by abstracting a hydrogen atom from an adjacent 
polyunsaturated fatty acid and the cycle continues.
Lipid peroxides have the capacity to directly compromise glutamate transport 
through oxidation and structure alteration of the glutamate transporters. However, due to 
the non-specific and indiscriminate nature of most ROS, a change in glutamate transport 
may not imply that the oxidative insult is acting only at the site of the glutamate 
transporter. Upon exposure to ROS, other membrane proteins (ATPases, ion channels, 
receptors) essential for the energy and membrane potential requirements of glutamate 
neurotransmission, could indirectly alter glutamate transport. Therefore, understanding 
the vulnerability of the transporters to ROS damage is necessary to begin deciphering 
mechanisms of glutamatergic dysfunction.
The EAATs may be especially susceptible membrane proteins. It is believed that 
the transport activities of GLTl (EAAT2), GLAST (EAATl) and EAACl (EAAT3) are 
equally inhibited by oxidants through direct modification of the protein (Trotti et al., 
1998). Commonly, targets of oxidation on proteins are cysteine sulfhydryl groups (Radi, 
1991 #125) and the EAATs contain varied amounts of cysteine residues, two of which 
are conserved among all the subtypes, except for EAATS, which has only one conserved 
cysteine (Kanner et al., 1993; Arriza et al., 1994; Fairman et al., 1995). 
Electrophysiological studies demonstrate that glutamate transport is inhibited and current 
flux decreased with the oxidation of sulfhydryl groups by 5,5’-dithio-bis(2-nitrobenzoic) 
acid (DTNB), and that the thiol-reducing agent dithiothreitol (DTT) reverses the
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inhibition and restores the current flux (Trotti et al., 1997). This finding demonstrates that 
the chemical redox state of reactive cysteine residues may serve to regulate glutamate 
uptake. Direct application of oxidants HjOj and xanthine/xanthine oxidase (X/XO) 
brought about a marked decrease (20% and 40% inhibition) in glutamate uptake in 
cultured astrocytes with no significant parallel release of lactate dehydrogenase. This 
suggests that glial cell viability is not jeopardized when glutamate transport is inhibited 
by ROS. Inhibition was prevented and partially restored with thiol reducing agents (DTT 
and GSH) but could not be restored or prevented with lipophilic antioxidants nor were 
any lipid peroxidation products present (Volterra et al., 1994). These findings indicate 
that in response to oxidizing agents, glutamate transport inhibition occurs independently 
from changes in cell viability or lipid alteration, and is primarily attributed to cellular 
changes occurring at the protein level.
D e f e n s e s  A g a i n s t  t h e  T h r e a t  o f  ROS i n  t h e  CNS
The presence of ROS is compensated by the cell through endogenous antioxidant 
defenses. It is when the defenses of the cell are overcome by the generation of oxygen- 
derived species that oxidative stress exists (Halliwell, 1992). Under normal physiological 
conditions, electron extraction by unstable free radicals and their precursors is primarily 
prevented by both enzymatic and non-enzymatic detoxification systems. This is not to 
say that some level of ROS activity occurs and may even be required for cellular 
communication and regulation. Important enzymatic antioxidants include glutathione 
peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD). GPX and CAT 
catalyze the reduction of hydrogen peroxide to water and molecular oxygen. The SOD
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enzymes convert superoxide to hydrogen peroxide and water. Ascorbate, a-tocopherol, 
and glutathione are examples of non-enzymatic molecules that form stable intermediates 
with free radicals and terminate free radical chain reactions and limit macromolecule 
damage (for review see Halliwell, 2001). Ascorbate is water-soluble and serves to 
detoxify free radicals such as hydroxy radical and superoxide. a-Tocopherol is a lipid- 
soluble antioxidant and primarily protects against deleterious lipid peroxidation cycle in 
cellular membranes. Glutathione (GSH) is a major cellular thiol that is afforded 
substantial reducing power through it’s sulfhydryl-group containing cysteine residue. 
GSH is unique in that it participates in both enzymatic and non-enzymatic antioxidant 
processes (i.e. GSH can scavenge H 2 O2  through the action of glutathione peroxidase 
(GPx) and act as a direct thiol reducing agent)(Orlowski et al., 1976; Meister et al., 
1983).
Glutathione is present in virtually all cell types and is the most prevalent
antioxidant in the mammalian central nervous system. The precursor amino acids of 
glutathione (cysteine, glutamate, and glycine) react to form GSH in two ATP-dependent 
synthesis steps (Figure 4). GSH has been found to comprise 91% of the acid-soluble 
thiols in the cerebral cortex and approximately 80% of the total soluble thiol groups in 
the cerebral cortex. In whole brain, the concentration of total glutathione, consisting of 
both its oxidized and reduced forms, is 0.5-3.4 pmoles/gm tissue (Orlowski et al., 1976). 
Histochemical and biochemical methods reveal that GSH is localized primarily in 
astrocytes(Slivka et al., 1987; Sagara et al., 1993; Ben-Yoseph et al., 1996), which 
consequently can withstand higher concentrations of H2 O2  induced toxicity than neurons 
(Raps et al., 1989; Philbert et al., 1991; Desagher, 1996). Increasing evidence suggests
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that cells with depleted levels of glutathione are more vulnerable to the oxidative 
products of normal respiration, implicating glutathione as the primary antioxidant 
responsible for maintaining redox homeostasis (Murphy et al., 1990; Ben-Yoseph et al., 
1996; Halliwell, 2(X)1). In a pathological setting, it has been hypothesized that one link 
between dopaminergic cell death in the substantia nigra and the concomitant decrease in 
glutathione observed in patients with Parkinson’s disease may be the accumulation of 
oxidants.
Maintaining intracellular GSH levels is largely dependent upon the availability of 
the rate-limiting precursor cysteine (Orlowski et al., 1976; Bannai, 1986). Cystine, 
transported through the Na^-independent system X q\  is reduced intracellularly and 
thought to be the primary source of cysteine for GSH synthesis in astrocytes and glioma 
cell lines (Cho et al., 1990; Sagara et al., 1993). The intracellular glutamate pool 
(maintained by glutamate uptake through the EAATs and glutamine deamination 
following glutamine uptake) is responsible for charging cystine uptake and maintaining 
intracellular GSH levels. Rimaniol and colleagues demonstrated that adding glutamate to 
the culture media increases intracellular GSH in a dose- dependent manner as long as 
sufficient cystine was present. The increase in GSH was not observed when glutamate 
was added in the presence of an EAAT inhibitor. Likewise, consistent with the 
competitive interaction of system X^- substrates, when the glutamate gradient is 
essentially reversed and the extracellular glutamate concentration is 1-lOmM, cystine 
uptake is inhibited and GSH levels drop (Murphy et al., 1990; Sagara et al., 1993; 
Rimaniol et al., 2001). These results establish that glutamate transport through the 
EAATs maintain GSH levels by providing precursor molecule and establishing
22
ATP ADP + Pi 
\  /
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Figure 4 The metabolism of glutathione. The rate-limiting reaction for GSH synthesis 
is catalyzed by gamma-glutamylcysteine synthetase (1). y-GIutamylcysteine and glycine 
then react to form the final product in the second synthesis step, which is catalyzed by 
GSH synthetase (2). As GSH scavenges oxidants and free radicals it is converted to the 
oxidized form GSSG through the action of GSH peroxidase (3). Regeneration of GSH 
from GSSG requires the reducing cofactor NADPH and the enzyme GSH reductase (4). 
(Orlowski et al., 1976; Meister, 1991; Meister, 1995).
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a glutamate pool allowing for the exchange of extracellular cystine for intracellular 
glutamate through system Xq (Igo Jr. et al., 1998; Rimaniol et al., 2001).
Maintaining GSH levels in astrocytes is not only important for their own viability, 
but also for the protection of neurons, both directly with GSH and indirectly by providing 
neurons with precursors following the extracellular catabolism of GSH (Sagara et al., 
1993; Schipper, 1996; Drukarch et al., 1997). Even though neurons are thought to exhibit 
cystine transport activity (Murphy et al., 1990; Sagara et al., 1993; Sagara et al., 1993) it 
is not likely to be through system as the neuronal uptake (Murphy et al., 1990) 
appears to exhibit different pharmacology than that in astrocytes (Cho et al., 1990). 
Additionally, northern blotting (Sato et al., 2002), and substrate immunoreactivity studies 
(Pow, 2001) indicate that system is predominantly expressed in glia. Neurons are 
thought to obtain the rate-limiting GSH precursor cysteine through direct uptake 
mechanisms (Zerangue et al., 1996; Chen et al., 2003) that when inhibited lead to a 
decrease in GSH synthesis (Chen et al., 2003). What is most important, with respect to 
GSH, is that independent of the neuronal or glial mechanism of cystine uptake, when the 
availability of intracellular cysteine is limited, GSH levels are attenuated.
Among the cellular antioxidant systems in the CNS, GSH is the most intimately 
connected with glutamate uptake. Ultimately, lowering the levels of glutathione in cells 
increases their sensitivity to excitotoxicity and oxidative stress (Bridges et al., 1991; Ben- 
Yoseph et al., 1996) and neurodegeneration is often a consequence (Ben-Yoseph et al., 
1996; Schulz et al., 2000)
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G l u t a m a t e  T r a n s p o r t  a n d  a  C y c l e  o f  E x c i t o t o x i c i t v  a n d  ROS F o r m a t i o n  
The progression of many CNS pathologies, both acute neurological insults such as 
ischemia, trauma, and hypK>glycemia as well as the chronic disease states such as 
Huntington’s, ALS, Alzheimer’s, and aging, may be a direct consequence of 
excitotoxicity and oxidative stress. One concept currently gaining acceptance is that 
excitotoxicity and oxidative damage may not be independent phenomena (for review see 
Trotti et al., 1998). Studies have shown that ROS are capable of inhibiting glutamate 
uptake directly (Piani et al., 1993; Volterra et al., 1994; Trotti et al., 1997; Rao et al., 
2003). Because glutamate transport is responsible for regulating extracellular glutamate 
levels, a loss in transport activity can lead to excitotoxicity. Therefore, glutamate 
transport activity serves as a possible link between the potentially pathogenic events of 
oxidative stress and excitotoxicity.
Interestingly, it is now thought that one consequence of excitotoxicity is the 
production of ROS. As discussed earlier, excess glutamate levels are widely accepted to 
initiate excitotoxicity by stimulating NMDA receptors leading to inordinate Ca^  ̂influx 
(Choi, 1987; Reynolds et al., 1995). Calcium is thought to induce ROS production 
through a number of cellular targets, the combination of which most probably contributes 
to the observed presence of ROS in excitotoxic episodes (Lipton et al., 1994; Choi, 1995; 
Juurlink et al., 1998; Halliwell, 2001). In mitochondria, Ca^  ̂accumulation disrupts the 
mitochondrial membrane potential (Schinder et al., 1996) and has been shown to 
uncouple electron transfer from ATP synthesis leading to free radical generation (Dugan 
et al., 1995; Reynolds et al., 1995; Schinder et al., 1996). Another important source of
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ROS attributed to NMDA-mediated Ca^  ̂influx is phospholipase Aj, which is thought to 
be activated by Ca^  ̂and cause the release of arachidonic acid (Lazarewicz et al., 1990; 
Manzoni et al., 1997), the metabolism of which can be a source of ROS. Calcium also 
leads to the activation of xanthine oxidase, the enzyme responsible for the oxidation of 
hypoxanthine to xanthine and then uric acid, simultaneously producing O2* and H2 O2 . 
The synthesis of NO* in the CNS is through a constitutive Ca^Vcalmodulin-dependent 
form of NOS (Marietta, 1994). Activation of nNOS can lead to glutamate release from 
synaptosomes (McNaught et al., 1998), OONO formation (for review see Juurlink et al., 
1998), and *OH formation (Lancelot et al., 1998). Therefore, if NMDA activated Ca^  ̂
influx resulting from excitotoxic levels of glutamate can produce ROS (Dugan et al.,
1995; Reynolds et al., 1995; Rao et al., 2003), and ROS can inhibit glutamate transport, 
then transport activity does not merely link independent events of oxidative stress and 
excitotoxicity, but mediates the development of a potentially destructive cycle (Figure 5).
The existence of an excitotoxic cycle is sometimes best illustrated when 
examining acute neuronal pathologies such as trauma and ischemia. In traumatic neuronal 
injury, high levels of glutamate are thought to arise at an injury site due to damaged 
neurons, thereby initiating excitotoxicity in surrounding neurons. Soon after injury, 
inflammatory mediators and microglia, specialized macrophages of the CNS, are capable 
of releasing glutamate and free radicals, expanding the range of injury (Piani et al., 1993). 
Over-activation of glutamate ionotropic receptors and subsequent Na* and Ca^  ̂entry may 
also lead to the production of ROS, possibly impairing glutamate transport by interacting 
with the transporters themselves, or other membrane proteins and lipids, both escalating 
and expanding the scope of injury by further elevating glutamate levels. Additionally,
26
Na^ and Ca^  ̂influx may lead to a depletion of ATP as ATPases attempt to restore ionic 
balances. At this point of energy deficiency, the pathology of trauma and ischemia 
overlap. In situations of ischemia, a disruption of blood flow causes a reduction in 0%, 
and ATP shortage often results. Whatever the cause, glutamate levels are also known to 
increase dramatically during energy failure (Choi et al., 1990; Lipton et al., 1994;
Juurlink et al., 1998; McNaught et al., 1998; Zeevalk et al., 1998). The transporters 
derive their energy to accumulate glutamate intracellularly from ion gradients that 
ultimately are set up by the Na7K^ ATPase. Under ischemic conditions, NaVK^ ATPases 
are unable to function, Na^ permeability is disrupted and membrane potentials are 
reduced. As Na^ begins to increase inside cells, glutamate is released for at least three 
reasons (1) the Na^-gradient is no longer able to drive and maintain the glutamate 
gradient and thus intracellular glutamate can travel through the transporters in reverse, (2) 
Na^ influx will depolarize the cells allowing for increased synaptic release of glutamate, 
and (3) cell-swelling- induced release of glutamate may also occur as a result of the 
diminished NaVK"̂  ATPase activity (Lipton et al., 1994; Takahashi et al., 1997; Seki et 
al., 1999). Clearly, the consequences of increased glutamate levels is eventually even 
higher glutamate levels, a self-perpetuating and self-destroying excitotoxic cycle.
In addition to acute pathologies such as ischemia, the co-dependence of 
excitotoxicity and ROS production for the establishment of chronic neurodegenerative 
diseases such as ALS, (Rao et al., 2003) Huntington’s chorea, (McGeer et al., 1978) 
Alzheimer’s disease (Ying, 1997), and aging (Ying, 1997) is also gaining acceptance 
(Lipton et al., 1994; Halliwell, 2001) and has become the premise for which therapeutic 
interventions are based (Juurlink et al., 1998; Halliwell, 2001).
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Figure 5. Glutamate transport and a cycle of excitotoxicity and ROS formation
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specific Aims
R a t io n a l e
The present study was undertaken to examine the sensitivity of glutamate transport to a 
mild oxidative insult produced by glutathione depletion. The production of reactive 
oxygen species (ROS) is one mechanism that may adversely affect glutamate transport. 
Excessive oxidative stress has been shown to inhibit the glutamate transporters (Piani et 
al., 1993; Volterra et al., 1994; Trotti et al., 1997; Rao et al., 2003). Following inhibition 
of the EAATs, extracellular glutamate levels increase and can accumulate to excitotoxic 
levels, which, in time, can lead to excessive ROS production. The result of glutamate 
transport inhibition and ROS production can often be more than additive and propagation 
of one another can create a destructive cycle. Understanding the sensitivity of the 
transporters to ROS-mediated damage is necessary for deciphering excitotoxic and 
possibly pathogenic events involving glutamate neurotransmission.
A common approach to study the relationship between excitotoxicity and 
oxidative damage has been to introduce oxidants at levels high enough to induce 
excitotoxicity and death. Allowing cells to exist in an environment in which GSH levels 
are lowered provides a new, and possibly, more relevant way to study the link between 
excitotoxicity and oxidative stress with the primary focus being the vulnerability of 
glutamate transport.
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E x p e r im e n t a l  A p p r o a c h
AIM 1: Characterize the Na^-dependent uptake activity in primary astrocytes and assay 
for intracellular glutathione.
Hypothesis: Long-term cultures of primary astrocytes exhibit stable levels of Na^- 
dependent glutamate transport activity and intracellular glutathione.
Rationale: As glia are thought to be responsible for the majority of glutamate transport 
and glutathione synthesis, evidence of these processes should exist in primary astrocyte 
cultures.
Specific Experiments
1. Determine the subtype of glutamate transporter present in primary astrocytes.
2. Examine the pharmacological activity of the glutamate transporter expressed in 
primary astrocytes.
3. Establish the rates of ̂ H-D-aspartate uptake through the glutamate transporters in 
primary astrocytes over a 28-day time course.
4. Use the glutathione recycling assay to moniter total glutathione levels.
AIM 2: Assess the sensitivity of ̂ H-D-aspartate uptake activity in astrocytes chronically 
treated with an inhibitor of glutathione synthesis, buthionine sulfoximine (BSO)
Hypothesis: Glutamate transport activity is sensitive to endogenous oxidative stress 
produced by the chronic depletion of glutathione.
Rationale: The transport process has been shown to be sensitive to oxidative stress. 
Endogenous levels of ROS produced as a consequence of normal cellular metabolism 
may normally be scavenged by glutathione. The depletion of glutathione by BSO may 
cause oxidative stress sufficient to attenuate transport activity.
Spgçifjç EXPRCW W S
1. Quantify glutathione levels is primary astrocytes
2. Quantify glutathione levels in astrocytes chronically treated with BSO
3. Establish the rates of ̂ H-D-aspartate uptake through the glutamate transporters in 
primary astrocytes chronically treated with BSO
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AIM 3. Assess the sensitivity of ̂ H-D-aspartate uptake activity in astrocytes chronically 
depleted of glutathione to an acute challenge of mild oxidative stress.
Hypothesis: Glutamate transport activity in astrocytes with depleted levels of 
intracellular glutathione may be more sensitive to a mild exogenous oxidant exposure.
Rationale: High levels of exogenously applied oxidants have been shown to inhibit 
transport. The attenuation of transport by sub-toxic levels of oxidants may be increased in 
astrocytes with depleted glutathione levels.
Specific Experiments
1. Apply moderate concentrations of H2O2  and X/XO to astrocytes
2. Apply moderate concentrations of H2 O2  and X/XO to BSO treated astrocytes
3. Establish the rates of ̂ H-D-aspartate uptake through the glutamate transporters in 
astrocytes receiving the acute challenge
AIM 4. Assess the levels of oxidative stress in astrocytes by measuring secondary 
markers of ROS and oxidative stress.
Hypothesis: As a result of oxidative stress produced by glutathione depletion and the 
added ROS, a change in tryptophan fluorescence should be observed that is indicative of 
protein/ROS interactions.
Rationale: ROS are often too labile to measure directly. A known marker of oxidative 
stress in proteins is the oxidation of tryptophan residues in proteins. This oxidation is 
associated with a measurable decrease in fluorescence. Protein oxidation is thought to be 
more sensitive than other techniques and is especially relevant to transporter inactivation. 
Using this technique, the effects of BSO and oxidants can be examined.
Specific Experiments
1. Assess the levels of protein oxidation in astrocytes treated with BSO using 
tryptophan fluorescence.
2. Assess levels of protein oxidation associated with acutely challenged 
astrocytes using tryptophan fluorescence.
3. Assess levels of protein oxidation in both BSO-treated and acutely challenged 
astrocytes using tryptophan fluorescence
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Materials and Methods 
P r i m a r y  A s t r o c y t e  C u l t u r e
DMEM/F-12, (GibcoBRL CAT# 12400-024); 0.22 um membrane filter, (Fischer 
CAT#09-761-50); N-2-Hydroxyethylpiperazine-n-2-ethanesulfonic acid (HEPES),
(Sigma H9136); Bovine serum albumin, (Sigma A7888); Hank’s Balanced Salt Solution, 
(BBSS) (Gibco 310-4180 AG); Penicillin/Streptomycin, (Gibco 600-5140 PE); 
Fungizone, (Gibco 600-529 AE); Fetal Bovine Serum, (heat inactivated) (Gibco 230- 
6140 AJ); Trypsin, (Gibco 610-5055 AG); sodium pyruvate, sodium bicarbonate, and 
EDTA were purchased from Sigma. 12 well Coming Costar polystyrene plates, (Fisher 
0720082); 150 cm^ cell culture flasks, (Fisher 430824); L-buthionine-[S,R]- sulfoximine 
(BSO), (Sigma B-2515)
Primary astrocytes were prepared based on a standard protocol (McCarthy et al., 1980).
In brief, three 3-4 day-old Sprague-Dawley rat pups were sacrificed and the brains placed 
into a 60 mm dish containing Ca^ /̂Mg^  ̂free buffer (CMF) on the stage of a dissecting 
microscope. The meninges were removed, brain divided into hemispheres, and the 
midbrain and hippocampus dissected out. The remaining cerebral cortices were washed in 
CMF and triturated in a 15 ml centrifuge tube with a 10 ml pipette. Tissue was incubated 
for 10 min in 37° C water bath and centrifuged in clinical centrifuge for 3 minutes. The 
pellet was suspended in 6 mis DMEM / F12 W / 15% FBS, triturated with a flame- 
constricted siliconized glass pipette, and suspension was evenly distributed (2ml) into 
three 150 cm^ flasks containing 30 mis DMEM / F12 W /15%  FBS. Following a 24 hr
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incubation at 37° C, cells were rinsed with lOmls DMEM/ F12 and fed with 30 mis of 
DMEM/ F12w/ 10% FBS. Every 4 days, cells were fed with 30 mis of fresh DMEM/ F12 
w/ 10% FBS. On day 8, flasks were shaken at 280 rpm for 24 hours, rinsed with DMEM/ 
F12, fed with 30 mis of DMEM/ F12 w /10% FBS, and allowed to incubate at 37° C for 
five days. Following purification, the 14 day old primary astrocyte culture cells were 
harvested with 0.25 % Trypsin solution, transferred to 50 ml tubes, centrifuged for 5 min, 
pellet suspended in DMEM/ F I2 w/ 10%FBS, triturated with a flame-constricted 
siliconized glass pipette, and counted. Cells were then plated on 12-well plates at a 
density of ~ 25,000 cells/well. Seven to eight days post-plating astrocytes reach 
confluency and were designated as experimental day 0. Feeding took place every 4 days 
up to 28 days with DMEM/ F12w /10% FBS for controls and DMEM/ F12w/ 10% 
FBS/500 pM BSO in treated wells. D-Aspartate uptake assays were performed on 
experimental days 1,7, 14, and 28 post-plating (22, 29, 36,50 days in culture 
respectively) depending upon experimental conditions (days 1 and 7 only for H2 O2 and 
X/XO insult).
G l u t a t h io n e  R e c y c l in g  A s s a y
Sulfosalicylic acid, (Sigma S-2130); Glutathione, (Sigma G-6529); NADPH, (Sigma N- 
1630); Glutathione reductase, (Roche 105-678); DTNB, (Sigma D-8130)
Quantification of total GSH was achieved using an enzymatic-recycling assay described 
by Anderson, 1985 (Anderson, 1985). 5, 5’-dithiobis-2-nitrobenzoic acid (DTNB) serves 
to oxidize GSH to GSSG with stoichiometric formation of 5-thio-2-nitrobenzoic acid
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(TNB). GSSG is reduced to GSH by GSH reductase and NADPH. The rate of TNB 
production was monitored at 405 nm for 5 minutes on a Molecular Devices ThermoMax 
Microplate spectrophotometer and represents total glutathione content. On day of assay 
primaiy astrocytes were harvested at 20-48 days old (1-28 days post-plating), 
homogenized in 1% sulfosalicylic acid (SSA), microfuged for 1 min, and kept at 4®C 
until use. The assay was performed by combining 50 ml each of DTNB, NADPH, GSH 
reductase, and sample (supernatant) in a 96-well microplate. The final concentrations 
were as follows: 0.6 mM DTNB, 0.2 mM NADPH, and 0.66 U/ml GSH reductase.
^ H -D -A s p a r t a t e  T r a n s p o r t  A s s a y s
Assay buffer (1 liter): CaCli (l.lm M ), MgS0 4 »7 H2 0  (0.71 mM), D-Glucose (5.5mM), 
HEPES (lOmM), HBSS: KCl (0.4 g/L), KH2 PO4  (0.06 g/L), NaCl (8.0 g/L), 
Na2 HP0 4 *7 H2 0  (0.09 g/L), D-Glucose (1.0 g/L). Xanthine (X) Sigma X-0626; xanthine 
oxidase (XO) (Sigma X-4500); H2 O2 , (Mallinckrodt AR 5240); Dimethyl sulphoxide 
DMSO (Sigma D-2650); D-aspartate (Sigma A-8881); ^H-D-aspartate obtained in 1.0 
mCi vials, S.A. 15.60 Ci/mmol fi*om Perkin Elmer Life Sciences Inc.; SDS, (Bio-Rad 
161-0416).
On the day of the assay, untreated astrocytes and astrocytes treated with BSO were 
removed from 3TC  incubation, media was removed, replaced with assay buffer and 
either assayed for D-aspartate uptake (in the presence or absence of DHK 250^iM FV and 
BSO 500[iM FV) or insulted first with X/XO (500pM/5mU/ml FV) or H2 O2  (50^M FV), 
incubated at 37^C for 15 minutes, and subsequently assayed. The D-aspartate uptake
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protocol in short is as follows: 12-well Costar plates containing primary astrocytes were 
incubated for 5 minutes in HBSS control buffer pH 7.4 in water bath at 30°C. Control 
buffer was aspirated and FV 25 pM ^H-D-Aspartate was aliquoted to each well. 
Following a 5-minute incubation, uptake was immediately stopped through aspiration of 
substrate and quenching with ice-cold control buffer. 0.4N NaOH was added to each 
well and allowed to shake slowly for 24 hrs. 200 pi aliquots were then transferred to vials 
with 4-6 pi glacial acetic acid and 3.5 mis Liquiscint. The rate of ̂ H-D-aspartate uptake 
was quantified through liquid scintillation counting, corrected for non-specific uptake at 
4**C, and normalized for protein using the BCA method.
IMMUNOBLOTTING
Complete lysis buffer, (Roche); 10% Tris-HCl gel, (Bio-Rad); Hybond-P PVDF 
membrane, (Amersham Pharmacia Biotech); anti-rat GLAST, (Alpha Diagnostic 
International); rOLT-1, (Affinity BioReagents); donkey anti-rabbit IgO-F(ab’)2-HRP, 
(Amersham Biosciences); anti-biotin, (Cell Signaling); ECL reagents, (Amersham 
Biosciences); Versadoc Imaging System, (Bio-Rad).
Cultured astrocytes grown in 150 cm^ dishes were washed and harvested on days 20 and 
34 (day 1 and 14 post-plating) in cold PBS. Cell suspension was spun at 1000-1200 RPM 
(#3) for 10 minutes, the supernatant was removed and cell pellet was immediately put on 
ice. Pre-chilled C0mplete lysis buffer was added to pellet (0.25 mls/dish) and cells were 
homogenized on ice with a 27-gauge needle. Protein was quantified using the Bradford 
assay and stored at -20°C until use. On the day of the immunoblot, samples were thawed
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on ice and denatured by boiling for 5 minutes in IX Laemmli buffer. Proteins were 
separated using SDS-polyacrylamide gel electrophoresis in Tris/glycine/SDS buffer 
between 120-150 volts on a 10% Tris-HCl gel. Proteins were transferred to a Hybond-P 
PVDF membrane in tris/glycine/20% methanol pH 8.3. Molecular weight standards were 
obtained from Cell Signaling. GLAST blots were blocked in 0.1% skim milk/tris- 
buffered saline (20mM Tris Base/130mM NaCl) 0.1% Tween (pH 7.6) for 1 hour and 
then probed with affinity purified rabbit anti-rat GLAST against a 15 aa synthetic peptide 
near the C-terminus of rGLAST at 1:250 at 4°C overnight. GLT-1 blots were blocked in 
0.5% skim milk/tris-buffered saline (20mM Tris Base/130mM NaCl) 0.1% Tween (pH 
7.6) for 1 hour and then probed with rabbit anti rGLT-1 antiserum against a 17 aa 
synthetic peptide at 1:1000 at 4®C overnight. Following probing, blots were incubated 
with donkey anti-rabbit IgG-F(ab’)2-HRP (Amersham Biosciences) at 1:5000 and anti­
biotin at 1:1000 in 0.1% or 0.5% milk TBS/Tween for 1 hour at room temperature. 
Immunoreactive proteins were visualized using enhanced chemiluminescence (ECL) on 
the Versadoc Imaging System.
T r y p t o p h a n  F l u o r e s c e n c e
Tryptophan residues account for the majority of protein fluorescence. A microplate 
fluorometer using Softmax Pro software was used for relative fluorescence readings in 
astrocytes (treated and untreated) as follows: On day of harvesting, DMEM/F12 w/ 10% 
FBS was removed from astrocytes, washed with HBSS 2x, and scraped in 1% SSA when 
looking at the effect of BSO over the 28 day course. For cells to be insulted, assay buffer 
was added following the wash. Astrocytes (BSO treated or un-treated) were then exposed
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to either X/XO (500^M/5mU/ml FV) or H2 O2  (50piM FV) at 20-27 days old (day 1 and 7 
post-plating) and allowed to incubate at 37°C for 15 minutes as in uptake experiments. 
Following insult incubation, cells were harvested from 12-well tissue culture plates in 1% 
SSA and homogenized. Following protein determination, equivalent amounts of protein 
were centrifuged on a high-speed microfuge, resuspended in 1% SDS, re-homogenized, a 
maximum wavelength spectrum is run, and the relative fluorescence determined. Bovine 
serum albumin (BSA) experiments were performed in 100 pi of the indicated solvents at 
the given protein amounts and the relative fluorescence determined.
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Results
Transporter function is credited with maintaining proper glutamate homeostasis at the 
synapse. Because the central goal of this work was to reveal the vulnerability of 
glutamate transport to oxidative inactivation, it was important to identify a cell culture 
system that expressed glutamate transporters. A primary culture of cortical astrocytes was 
utilized for this study. This culture system was chosen as glia are thought to account for 
the majority of glutamate uptake in the brain, expressing both GLAST and GLT-1 
(Rothstein et al., 1994; Rothstein et al., 1996; Swanson et al., 1997). Additionally, 
astrocytes are a major source of glutathione synthesis in the CNS (Slivka et al., 1987; 
Raps et al., 1989; Philbert et al., 1991; Sagara et al., 1993), making them an appropriate 
choice for an antioxidant-depletion model of oxidative insult. As a primary culture, the 
astrocytes are also considered more relevant than an immortalized model.
A s t r o c y t e s  E x h i b i t  T y p i c a l  M o r p h o l o g y  a n d  P r i m a r i l y  E x p r e s s  G L A S T  
Astrocytes were isolated from 3-4 day old rat pups, purified, and after 22 days in culture 
(experimental day 1), were visualized on an Olympus 1X70 microscope at 20x 
magnification and photographed through a Hoffman Modulation Contrast lens using 
Wasabi software. Essentially pure cultures of astrocytes (>98%) are obtained using this 
method (McCarthy et al., 1980). The primary cells appear to grow in flat sheets and 
exhibit the typical polygonal morphology of an undifferentiated neuron-free culture 
(Figure 6) (Swanson et al., 1997; Schlag et al., 1998).
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Transporter expression in the primary astrocytes was confirmed through 
immunoblotting for the two transporter subtypes known to be expressed in glia (Rothstein 
et al., 1994). Anti-peptide antibodies were obtained for rGLT-1 (ABR) and rGLAST 
(Alpha Diagnostic) and used to examine the presence of GLAST and GLT-1 in the 
primary astrocyte cell lysate. Proteins were separated using SDS-polyacrylamide gel 
electrophoresis in Tris/glycine/SDS buffer between 120-150 volts on a 10% Tris-HCl gel 
(Bio-Rad). Rat cerebellum lysate was used as a positive control for both GLAST and 
GLT-1 blots. The expression of the GLAST subtype of glutamate transporter 
predominated in the primary astrocyte culture (Figure 7 and Figure 8). The anti-rGLAST 
antibody recognized a protein with a molecular weight of ̂ 50 kDa in both day 1 and day 
14 cultures. GLT-1 expression in astrocyte cultures was not detected. Lanes probed with 
anti-rGLT-1 reveal a ~90 kDa that is likely the result of nonspecific antisera binding. 
These results are consistent with findings cited in the literature (Rothstein et al., 1994; 
Swanson et al., 1997). Even though GLT-1 is a known glial glutamate transporter, when 
grown in isolation from neurons under normal culture conditions, astrocytes primarily 
express GLAST (Swanson et al., 1997; Schlag et al., 1998).
D-A s p a r t a t e  U p t a k e  A c t i v i t y  in  P r i m a r y  A s t r o c y t e s
Radiolabeled D-aspartate uptake was used to quantify the activity of GLAST in primary 
astrocytes. Kinetic studies have established both D-aspartate and L-aspartate as 
competitive inhibitors and substrates of both GLT- and GLAST (Bridges et al., 1999). 
-D-aspartate was chosen for uptake studies because it serves as a non-metabolizable 
glutamate analogue that is not present endogenously in cells (Drejer et al., 1983). In
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addition to the mean rate of uptake (see below), transport activity of GLAST was also 
determined in the presence of DHK (a selective inhibitor of GLT-1) (Arriza et al., 1994) 
and BSO (a glutamate analog that inhibits y-glutamylcysteine synthetase, yGCS)
(Meister, 1991). On experimental day 1 (22 days in culture) primary astrocytes were 
incubated with 25pM -D-Aspartate and 250pM DHK or 500pM BSO for 5 minutes at 
30°C. Nonspecific uptake was corrected for by subtracting accumulated ^H-D-aspartate at 
4°C. The rate of D-aspartate uptake in control astrocytes was 189 +/- 17.3 (pmol/min/mg 
+/- SEM). Neither DHK (163 +/- 12.1) nor BSO (218 +/- 2.14) had a large effect on D- 
aspartate uptake (Table 1). As a selective inhibitor for EAAT2 (GLT-1) (Arriza et al., 
1994) this data is consistent with a culture primarily expressing the GLAST subtype of 
glutamate transporters. The K; for DHK in mammalian cells expressing EAATl 
(GLAST) is in the millimolar range and in the micromolar range for EAAT2 (Bridges et 
al., 1999).
The inability of BSO to inhibit uptake is important for two reasons. ( I) As a 
glutamate analog and inhibitor of y-glutamylcysteine synthetase, it was important to 
demonstrate that its action did not involve inhibition of D-aspartate uptake at GLAST. (2) 
Although not directly related to this study, the result here indicates that the mechanism by 
which BSO gains access to the intracellular space is not through the glutamate 
transporter. Currently the mechanism of cellular entry by BSO is unknown. It is 
concluded from the pharmacology data and the western blots shown in Figure 7 and 
Figure 8 that the predominant source of D-aspartate uptake in the primary astrocyte 
culture is through GLAST.
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Following the inhibition studies, uptake experiments were performed in the 
astrocytes as a function of time in culture. On the day of the assay, untreated astrocytes 
(no BSO) at 20-48 days old (1-28 days post-plating) were incubated with 25 pM ^H-D- 
Aspartate for 5 minutes at 30°C. Nonspecific uptake was corrected for by subtracting 
accumulated ^H-D-aspartate at 4°C . As reported in Table 2 uptake rates for controls on 
days 1,7,14, and 28 are 201 +/- 34.5,359 +/- 39.1,419 +/- 75.3, and 386 +/-26.0 
respectively (pmol/min/mg +/- SEM).
Modest increases in uptake were observed after day 1 (Table 2), suggesting 
increased transporter expression in long-term cultures. This would not be surprising as 
trafficking of membrane proteins to the plasma membrane from an intracellular pool, 
(providing a highly efficient form of protein expression that may exist in lieu of and in 
conjunction with protein synthesis) is employed by many membrane proteins (GABA, 
dopamine, and serotonin transporters, GLUT4). Rapid changes in cell membrane 
expression of the glutamate transporters are known to occur, although the details are not 
completely elucidated (Robinson, 2002).
Protein levels throughout the time course remain consistent. Uptake rates were 
normalized for total cellular protein using the bicinchoninic acid assay and values of 
0.189 +/- 0.03,0.220 +/- 0.02, 0.233 +/- 0.012, and 0.266 +/- 0.029 (mg/ml +/- SEM) 
were obtained from the standard curve on days 1,7, 14, and 28 respectively (Figure 9). 
The astrocytes have reached ^-90% confluency on experimental day 0 and appear to 
maintain near maximal confluency throughout the time course.
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GSH L e v e l s  in  P r i m a r y  A s t r o c y t e s  a r e  D e p l e t e d  w i t h  BSO 
To quantify GSH levels within astrocytes a GSH recycling assays was used.
The method employed is a modification of that of Tietze (Anderson, 1985) whereby 5, 
5’-dithiobis-2-nitrobenzoic acid (DTNB) serves to oxidize GSH to GSSG with 
stoichiometric formation of 5-thio-2-nitrobenzoic acid (TNB). GSSG is reduced to GSH 
through the action of the GSH reductase and NADPH included in the assay. Following 
homogenization of cell samples, the rate of TNB production is monitored at 405 nm for 5 
minutes. Individual rates of TNB formation are determined for each amount of GSH and 
are used to generate a standard curve. A typical plot of individual rates over a range of 
GSH levels is depicted in Figure 10.
Originally, the rate of TNB formation for each standard and sample was carried 
out in individual cuvettes and absorbance recorded. To modify the procedure to a more 
time efficient microplate assay, the volumes of all reaction reagents (GSH, GSH 
reductase, DTNB, NADPH) were adjusted to accommodate the 200 p,l well volume on a 
96-well microplate. The final volume concentrations were as follows: 0.6 mM DTNB, 0.2 
mM NADPH, and 0.66 U/ml GSH reductase. The microplate GSH recycling assay was 
performed over a range of known amounts of GSH (0.04 to 2.5 nmol) to access the 
reliability of the procedure (Table 3). The percent recovery value for GSH was 
approximately 98% over the range of concentrations examined. Having established the 
reliability of the microplate assay, a compatibility study between the cuvette and 
microplate methods for the GSH recycling assays was performed with cell extracts. C6  
glioma cells were used to obtain a baseline for GSH levels as well as in cells treated with 
known GSH-depleting agents 4-S-CPG, a compound that limits the availability of the
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GSH precursor cysteine (Patel et al., 2004), and BSO, the inhibitor of the rate limiting 
step of GSH synthesis (yGCS) (Meister, 1991). Control values for nmols of GSH in both 
the cuvette and microplate samples were similar, 2.7 +/- 0.06 and 3.1 +/- 0.05 
respectively (nmol +/- SEM). Cells receiving 100 pM 4-S-CPG or 500 pM BSO using 
both the cuvette method (0.23 +/- 0.01, and 0.19 +/- 0.01) and the microplate method 
(0.20 +/- 0.02, and 0.16 +/- 0.01) yielded similar results (nmol +/- SEM) (Table 4). The 
data for 4-S-CPG and BSO is consistent with their ability to limit GSH synthesis and no 
significant difference was found to exist between the two methods.
The microplate assay was then employed to measure the amount of GSH in 
primary astrocytes as described in Methods. As in the previous uptake experiments 
(Table 2) the GSH content in astrocytes was examined as a function of time in culture.
On experimental days 1,7,14, and 28 (22,29, 36, 50 days in culture respectively) 
untreated (no BSO) primary astrocytes were found to contain 9.59 +/- 0.769, 8.34 +/- 
0.286,6.56 +/- 0.910, and 8.24 +/- 2.042 (mean GSH in nmol/mg +/- SEM) (Figure 11).
As with transport rates, there appears to be no effect of culture age on GSH levels. 
To more completely investigate the relationship between transporter function and GSH 
levels, D-aspartate uptake was assayed under GSH-depleted conditions. To insure that 
GSH within astrocytes could be effectively depleted, GSH levels were monitored 
following treatment with BSO. BSO is an effective inhibitor of GSH synthesis and has 
been shown to be less toxic and more selective than other GSH depleting agents (Meister, 
1991).
On experimental day 1, 500 pM BSO was introduced with normal growth media 
(DMEM/ F12w/ 10% FBS) to primary astrocytes incubated at 37®C. Over the next 24
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hours samples were assayed for GSH using the GSH recycling assay as described in 
Methods. At time 0 , 4, 8 , 12, and 20 hours samples were found to contain 4.0 +/- 0.31, 
2.3 +/- 0.09, 1.0 +/- 0.04, 0.7 +/- 0.4, and 0.3 +/- 0.09 respectively (mean GSH in 
nmol/mg +/- SEM) (Figure 12). This confirmed the findings of others that the time 
required for BSO to deplete total GSH levels was under 24 hours when using 500 pM of 
inhibitor (Bridges et al., 1991; Devesa et al., 1993; Drukarch et al., 1997). To then 
establish an astrocyte culture chronically depleted of GSH, treatment with 500 pM was 
carried out during routine media changes for 28 days and cells were harvested using 1 % 
SSA. On experimental days 1,7, 14, and 28 the GSH levels in the primary astrocytes 
were 1.64 +/- 0.292, 1.34 +/- 0.119,0.91 +/- 0.248, and 0.99 +/-0.424 (mean GSH in 
nmol/mg +/- SEM) (Figure 13). The difference between untreated and treated astrocytes 
over the time course amounts to a 6-7-fold decrease in intracellular GSH (Table 5). GSH 
content in BSO-treated cells expressed as the percent of control levels for days 1, 7, 14, 
and 28 were 17 +/- 1.8, 16 +!- 1.3, 13 +/- 2.2, and 11 +/- 3.2 (Table 5). As shown in 
untreated cells, the GSH values remain stable when treated with BSO over the time 
course.
It appears that there exists some level of residual GSH in the astrocyte culture 
(Table 5) as previously observed in other cells treated with BSO (Bridges et al., 1991; 
Devesa et al., 1993; Stokes et al., 2000). The inability to totally eliminate GSH levels 
may exist for a variety of reasons (Meister, 1991 for review). Because BSO inhibits the 
active site of 7 -glutamylcysteine synthetase and binds to the same site as glutamate, it is 
possible that a high levels of endogenous glutamate could compete with BSO inhibition 
of the enzyme. Negligible amounts of glutamate in the cellular media reduce the
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likelihood of this possibility. Alternatively, GSH levels can be independent of y- 
glutamylcysteine synthetase activity. This could occur if certain y-glutamyl amino acids 
produced by y-glutamyltranspeptidase are transported into the cell. For example, when 
cystine is the amino acid acceptor in this reaction, y-glutamylcystine is formed and is 
transhydrogenated to form y-glutamylcysteine, which can bypass the rate-limiting step 
and allow for minimal synthesis to take place. In addition to bypassing normal synthesis, 
a distinct subcellular pool of GSH unaffected by yGCS inhibition exists in mitochondria 
and could account for the residual levels of GSH (Meister, 1991). Mitochondria do not 
contain y-glutamylcysteine synthetase or GSH synthetase and thus BSO uptake is not 
relevant. A form of GSH transport is thought to exist instead and thus provides a way for 
mitochondria to detoxify the fraction of incompletely reduced oxygen during aerobic 
respiration (McNaught et al., 2000).
A s t r o c y t e s  C h r o n i c a l l y  D e p l e t e d  o f  GSH M a i n t a i n  N o r m a l  T r a n s p o r t  
A c t i v i t y
Once the glutamate transporter subtype and activity was characterized in the primary 
astrocytes, and a protocol for depletion of GSH was established, uptake experiments were 
performed to examine whether or not time in culture in combination with lowered GSH 
levels left the transporters vulnerable to endogenous oxidative damage. Astrocytes were 
treated with BSO during routine media changes and subsequently assayed on 
experimental days 1, 7, 14, and 28 post-plating (22,29, 36,50 days in culture 
respectively) for ^H -D-aspartate uptake. Nonspecific uptake was corrected for by 
subtracting accumulated ^H-D-aspartate at 4°C. Uptake rates for BSO-treated astrocytes
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are 204 +/- 38.4, 334 +/- 41.2, 341 +/- 50.6, and 366 +/- 29.0 on days 1,7,14, and 28 
respectively (pmol/min/mg +/- SEM) (Table 6 ). Uptake rates for astrocytes exposed to 
BSO do not differ significantly from controls as demonstrated by percent of control 
uptake +/- SEM for days 1,7,14, and 28 (i.e. 94 +/- 2.75,90 +/- 2.11, 84 +/- 5.10, and 90 
+/- 5.45, respectively) (Table 6 ).
These findings suggest that under the conditions examined, GLAST mediated 
uptake is insensitive to the endogenous oxidative stress that may occur as a result of 
depleted GSH levels. If the concentrations of GSH in cellular media is high, then there 
exists the possibility that masking of both extracellular effects of internally produced 
ROS and of externally applied ROS (which may have both intracellular and extracellular 
effects). To insure that additional GSH was not introduced exogenously, the cellular 
media was also assayed for GSH content. The GSH content in DMEM/F12 w/10% FBS 
was determined by spiking the media with known amounts of GSH. The GSH content 
was approximately 0.319 nmol/ml. This value is similar to the amount of GSH present in 
cells treated with BSO (using a mean protein value of 0.2268 mg/ml yields 0.277 
nmol/ml). It is concluded that the GSH level in the cell media is insufficient to overcome 
the effects of BSO in the astrocyte culture.
A M o d e s t  A c u t e  I n s u l t  o f  H 2O 2  a n d  X/XO A l t e r s  T r a n s p o r t  A c t i v i t y  in  
U n t r e a t e d  A s t r o c y t e  C u l t u r e s
To verify the sensitivity of glutamate transport function to oxidative damage, astrocytes 
were acutely treated with H2 O 2  and xanthine/xanthine oxidase (X/XO) at a concentration
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known to be non-toxic as determined by the release of the intracellular enzyme LDH 
(Volterra et al., 1994; Webster, 1998).
On the day of the assay (day 1 and day 7) astrocytes were exposed to either 50 
pM H2 O2  or 500 pM/5mU/ml X/XO for 15 min at 37°C and immediately washed in AB 
and assayed for D-aspartate uptake as described in Methods. On days 1 and 7 uptake was 
reduced in the presence of H2 O2  to 189 +/- 35.7 and 201 +/- 23.4 (pmol/min/mg +/- 
SEM). These values correspond to decreases of 81 +/- 5.338 and 71 +/- 6.346 (% of 
control uptake +/- SEM) (Table 7). Following X/XO exposure on day 1 and 7 uptake was 
decreased to 169 +/- 42.8 and 139 +/- 11.1 (pmol/min/mg +/- SEM), corresponding to 
percent of control values of 70 +/- 5.788 and 59 +/- 5.858 (% of control uptake +/- SEM) 
(Table 7). Higher doses of both H2 O2  (500p,M) and X/XO (500pM/50mU/ml) have been 
shown to decrease glutamate uptake in astrocytes without a significant parallel release in 
LDH (Volterra et al., 1994).
A  M o d e s t  A c u t e  I n s u l t  o f  H 2 O 2  a n d  X /X O  A l t e r s  T r a n s p o r t  A c t i v i t y  in  
G S H - d e p l e t e d  A s t r o c y t e  C u l t u r e s
In a subsequent series of experiments the same insult was applied to cells depleted of 
GSH. Astrocytes were treated at regular intervals with BSO and incubated with H2 O2  and 
X/XO as described in Methods. Table 8  indicates that for astrocytes treated with 50 piM 
H2O2  in the presence of 500 pM BSO on day 1 and day 7 the uptake was decreased to 141 
+/- 29.0 and 142 +/- 12.4 (pmol/min/mg +/- SEM), corresponding to percent of control 
values of 67 +/- 11.7 and 75 +/- 5.78 (% of control uptake +/- SEM). For those cells 
treated with 500uM/5mU/ml X/XO, results are similar for days 1 and 7, with uptake
47
decreased to 130 +/- 8.7 and 111 +/- 8.4 (pmol/min/mg +/- SEM), corresponding to 
percent of control values of 58 +/- 4.58 and 67 +/- 3.06 (% of control uptake +/- SEM) 
(Table 8 ). When the data for astrocytes exposed to HjOj and X/XO was compared to that 
for cells treated under the identical conditions, but with decreased GSH levels, no 
significant difference in the amount of D-aspartate uptake was observed (Figure 14).
E x p e r im e n t a l  C o n d it io n s  A r e  I n s u f f ic ie n t  t o  D e m o n s t r a t e  P r o t e in  
F l u o r e s c e n c e  C h a n g e s  in  A s t r o c y t e  C u l t u r e s
The fluorescence of the aromatic moiety on tryptophan residues has been used as an 
indicator of protein integrity in cell samples. Protein fluorescence is typically excited at 
280 nm, with emissions at 348 nm attributed to tryptophan residues along with tyrosine 
and phenylalanine. The fluorescence yield of tryptophan is much higher than the other 
two and has different lifetime in the exited state and explains why tryptophan is 
predominant in emission. A loss in fluorescence correlates with the oxidation of 
tryptophan (Davies et al., 1987; Jones et al., 1987; LeBel et al., 1991).
No detectable change in tryptophan fluorescence was observed in BSO-depleted 
astrocytes on experimental days 1 through 28. The choice of solvent was based on 
literature methods (Davies et al., 1987; LeBel et al., 1991) and pre-existing cell sample 
solutions available. BSO was administered with media changes (DMEM/F12 w/ 10% 
FBS) every fourth day in culture. Following protein determination, equivalent amounts of 
protein were centrifuged on a high-speed microfiige, resuspended in 1% SDS, re- 
homogenized, and relative fluorescence determined at ex 280X em 345k. The sensitivity 
of fluorescence to a protein range relevant to the cell homogenate (0.005mg-0.08mg) was
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tested in 1 % SDS with no appreciable difference seen within the range (data not shown). 
On days 1,7, 14, and 28 the fluorescence readings of BSO-treated astrocytes were 94.0 
+/- 5.37,93.0 +/- 3.74, 85.0 +/- 5.15, and 88.0 +Z-5.77 (% of control RFU +/- SEM ) 
(Figure 15). There were no indications that BSO treatment over 28 day time course was 
concurrent with protein damage as measured by tryptophan fluorescence.
As the methods indicate, the exposure of astrocytes to either HjOj or X/XO 
occurs in assay buffer (AB) and was allowed to incubate for 15 minutes at 37°C. The 
impact of this oxidant exposure is seen in uptake experiments as a loss in activity. If 
protein oxidation is taking place, it should be measurable using tryptophan fluorescence 
unless interference by the AB, the precipitation buffer (1% SSA) or by the solvent in 
which fluorescence is recorded (1% SDS), exists. To examine the quenching ability of 
these solutions, the tryptophan fluorescence of bovine serum albumin (BSA) exposed to 
oxidatants was assayed in both AB as well as 1% SDS (did not use 1% SSA because it 
precipitates protein and made homogenous sample prep difficult). BSA experiments were 
performed in lOOpl of the indicated solvents with 0.05 mg BSA and treated for 15 
minutes with a range of H2 O 2  concentrations. Over the 15 minute time period it took at 
least 1 0 0  pM H2 O2  to demonstrate significant changes in fluorescence values verses 
controls in both solvents (p = 0.0003 for AB and p = 0.003 for 1% SDS) (data not 
shown).
Untreated astrocytes (no BSO) were exposed to nontoxic levels of H2 O2 and 
X/XO as described in Methods on days 1 and 7 and assayed for tryptophan fluorescence. 
These cells received the identical treatment as those from Table 7 where D-aspartate 
uptake values were lowered upon insult exposure. Fluorescence values for day 1  and 7
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are as follows: Day 1 (control, 27251 +/- 1359; H^Oz, 27607 +/- 1897; X/XO, 27255 +/- 
1635, and 1% SDS, 669 +/- 96.5); Day 7 (control, 25222 +/- 1733; H^O ,̂ 26351 +/- 1579; 
X/XO, 26736 +/- 1563) (RFU +/- SEM) and are depicted in Figure 16. Unaltered RFU 
values over the seven-day time course were observed with both 50 pM HjOj and 500 
uM/5mU/ml X/XO treatment.
Under conditions of both oxidative insult and BSO treatment, fluorescence values 
for day 1 and 7 astrocytes were recorded as described in Methods. These cells received 
the identical treatment as those from Table 8 . The fluorescence values were as follows: 
Day 1 (control, 26638 +/- 1906; H^O ,̂ 27707 +/- 1576; X/XO, 27351 +/- 1639, and 1% 
SDS, 669 +/- 96.5); Day 7 (control, 25627 +/- 1730; H^O ,̂ 25763 +/- 1079; X/XO, 26184 
+/- 1275) (RFU +/- SEM) and are depicted in Figure 17. The values for the blank, 1% 
SDS, were 669 +/- 96.5. Similar to the untreated astrocytes (Figure 16), tryptophan 
fluorescence assays for BSO-treated astrocytes indicate no significant protein oxidation. 
Fluorescence values for untreated and BSO-treated astrocytes under oxidative insult are 
summarized in Figure 18. Exposure of primary astrocytes to moderate levels of oxidative 
insult appears to have different effects on uptake (see summary Table 9) and fluorescence 
(see summary Figure 18) but result in similar changes within each method when 
comparing untreated and BSO-treated cells.
50
m^mm'^ j4 ^ f '^ ; - é ’'..
Figure 6 . Day 1 prim ary astrocytes prepared from 3-4 day-old Sprague-Dawley ra t 
pups. Images were visualized on an Olympus 1X70 microscope at 20x magnification and 
photographed through a Hoffman Modulation Contrast lens using Wasabi software.
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Figure 7. Western analysis of day 1 prim ary astrocytes. Cell lysate from day 1 
cultures was subjected to SDS-polyacrylamide get electrophoresis at 120-150 volts on a 
10% Tris-HCl gel and immunoblotted with antibodies to KjLAST (A) and rGLT- 1  (B). 
Loading volumes (40 pi) and protein quantities were identical for both blots. Lane 1, 
MW standards; lane 2, cerebellum lysate (20pg); lane 3, astrocyte lysate (45pg).
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Figure 8 . W estern analysis of day 14 prim ary astrocytes. Cell lysate from day 14 
cultures was subjected to SDS-polyacrylamide get electrophoresis at 120-150 volts on a 
10% Tris-HCl gel and immunoblotted with antibodies to rGLAST (A) and rGLT-1 (B). 
Loading volumes (40 pi) and protein quantities were identical for both blots. Lane 1, 
MW standards; lane 2, cerebellum lysate (20pg); lane 3, astrocyte lysate (45pg).
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D-aspartate 25 pM 189+/-17.3
Dihydrokalnate 250 pM 163 +/-12.1
Buthionine sulfoximine 500 pM 218 +/- 2.14
Table 1. Pharmacological activity of ̂ H-D-aspartate uptake in primary astrocytes.
Uptake values in presence of 25 pM ^H-D-aspartate measured over 5 min at 30®C. 
Shown are mean values that arise from duplicate readings from duplicate sample wells 
+/- SEM values.
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Rate* of  ii[)takc' ( ptnol/niin/m^
Total Non­ Specific
(30X) specific
(4"C)
(Total -  ns)
1 218 +/- 35.9 17 +/- 4.3 201 +/- 34.5
7 377 +/- 40.4 18+/-2.4 359 +/- 39.1
14 446 +/- 75.0 27 +/- 8.6 419 +/- 75.3
28 412 +/- 29.4 26 +/- 4.7 386+/-26.0
Table 2. Uptake rates of ̂ H-D-aspartate :n untreated prim ary astrocytes. Uptake 
values in presence of 25 pM ^H-D-aspartate measured over 5 min at 30°C. Nonspecific 
uptake was corrected for by subtracting accumulated 3H-D-aspartate at 4°C. Shown are 
mean values that arise from duplicate readings of triplicate sample wells for independent 
experiments +/- SEM values for n = 5-11. p < 0.05 for day 1 verses day 14 groups.
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Figure 9. Mean protein values for astrocyte cell cultures. Proteins were solubilized in 
0.4M NaOH and values were obtained using the bicinchoninic acid method. Shown are 
mean values arising from triplicate readings per protein sample +/- SEM values for n = 5- 
11. No significant difference exists between groups.
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Figure 10. Rates of TNB formation corresponding to standard amounts of GSH. 
Above data was obtained by monitoring the rate of TNB production at 405 nm for 5 
minutes and represents total glutathione content. Each plot represents the mean rate of 
three identically treated wells. Plot represents a typical data set.
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2.5 98.2+/. 0.4
0.625 99.1 +/- 2.5
0.1563 97.7 +/- 2.2
0.039 99.1 +/- 2.7
Table 3. Percent recovery of known amounts of GSH In 1% SSA on the microplate 
spectrophotometer. Above data was obtained by monitoring the rate of TNB production 
at 405 nm for 5 minutes and represents total glutathione content. Mean values arise from 
three identically treated wells and are expressed as percent recovery +/- SEM.
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Microplate Cuvette
Control 3.1 +/- 0.05 2.7 +/- 0.06
4-S-CPG 0 . 2 0  +/- 0 . 0 2 0.23 +/- 0.01
BSO 0.16+/-0.01 0.19+/-0.01
Table 4. GSH values obtained from microplate and cuvette spectrophotometers in 
C 6  glioma cells. The volume of the samples are 4-fold larger for the cuvette (200 pi) 
verses the microplate (50 pi) and total GSH values were adjusted accordingly. Data 
represents mean values that arise from triplicate readings from duplicate sample wells. 4- 
S-CPG (100 pM), BSO (500 pM). No significant difference exists between values for the 
two methods.
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Figure 11. Levels of GSH in untreated primary astrocytes. On the day of the assay 
primary astrocytes are harvested at 22-50 days old (1-28 days post-plating), homogenized 
in 1% sulfosalicylic acid (SSA), microfuged for 1 min, and kept at 4°C until use. Above 
data was obtained by monitoring the rate of TNB production at 405 nm for 5 minutes and 
represents total glutathione content. Mean values arise from duplicate readings of three 
identically treated wells for each experiment and are expressed as nmol/mg +/- SEM for n 
= 3-5. No significant difference exists between groups.
60
I
I
COo
5
100
 y a -1.7380-I-514.61 X R^a 0.98738
80
4 50
40
-10
3
GSH (nmol)
2
1
0
0-5 5 10 15 20 25
Time (hours)
Figure 12. The time course of BSO-mediated loss of GSH. Primary astrocytes were 
treated with SOO^M BSO at 0 hrs and subsequently harvested at 0, 4, 8 , 12, and 20 hrs, 
homogenized in 1% sulfosalicylic acid (SSA), microfuged for 1 min, and kept at 4^C 
until use. Above data was obtained by monitoring the rate of TNB production at 405 nm 
for 5 minutes and represents total glutathione content. Individual data points represent 
mean values that arise from duplicate readings from duplicate sample wells. Plot shown 
represents a typical data set.
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Figure 13. Levels of GSH in BSO-treated astrocytes. On the day of the assay primary 
astrocytes are harvested at 22-50 days old (1-28 days post-plating), homogenized in 1% 
sulfosalicylic acid (SSA), microfuged for 1 min, and kept at 4®C until use. Above data 
was obtained by monitoring the rate of TNB production at 405 nm for 5 minutes and 
represents total glutathione content. Mean values arise from duplicate readings of three 
identically treated wells for each experiment and are expressed as nmol/mg +/- SEM for n 
= 3-5. No significant difference exists between groups.
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1 9.59 +/- 0.77 1.64 +/- 0.29 17 +/-1.8
7 8.34 +/. 0.29 1.34 +/- 0.12 16 +/-1.3
14 6.56 +/- 0.91 0.91 +/- 0.25 13 +/- 2.2
28 8.24+/-2.04 0.99 +/- 0.42 11 +/- 3.2
Table 5. Summary of GSH levels in untreated and BSO-treated astrocytes. On day of
assay primary astrocytes are harvested at 22-50 days old (1-28 days post-plating), 
homogenized in 1% sulfosalicylic acid (SSA), microfuged for 1 min, and kept at 4°C 
until use. Above data was obtained by monitoring the rate of TNB production at 405 nm 
for 5 minutes and represents total glutathione content. Mean values arise from duplicate 
readings of three identically treated wells for each experiment and are expressed as 
nmol/mg +/- SEM for n = 3-5. Day 1 (p < 0.0001), Day 7 (p — 0.0004), Day 14 (p = 
0.005), Day 28 (p = 0.0003) for untreated verses BSO-treated groups.
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1 0 201 +/. 34.5 100
500 204 +/- 38.4 94+/-2.8
7 0 359 +/- 39.1 100
500 334+/-41.2 90 +/- 2.1
14 0 419 +/. 75.3 100
500 341 +/. 50.6 84+/. 5.1
28 0 386 +/- 26.0 100
500 366+/-29.0 90 +/- 5.4
Table 6 . Uptake rates of ̂ H-D-aspartate in BSO (500|iM) treated astrocytes. Uptake 
values in presence of 25 p,M ^H-D-aspartate measured over 5 min at 30®C. BSO was 
administered with DMEM/F12 w /10% FBS feeding every fourth day in culture. Shown 
are mean values that arise from duplicate readings of triplicate sample wells for 
independent experiments +/- SEM values for n = 5-11. No statistically significant 
difference exists between rate or % control groups on each experimental day.
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1 Control 212 +/- 33.0 100
H2O2 189 +/- 35.7 81 +/- 5.34
Control 253 +/- 39.1 100
X/XO 169+/-42.8 70+/-5.79
7 Control 284 +/- 32.7 100
H2O2 201 +/- 23.4 71 +/- 6.35
Control 206 +/- 31.4 100
X/XO 139+/-11.1 59+/-5.86
Table 7. Effects of acute challenge on uptake values of ̂ H-D-aspartate in untreated 
astrocytes. On day of assay astrocytes are removed from 37®C incubation, media is 
removed and replaced with assay buffer and insulted with X/XO (500pM/5mU/ml FV) or 
H2 O2  (50pM FV), incubated at 37®C for 15 minutes. Uptake values in presence of 25 pM 
^H-D-aspartate measured over 5 min at 30®C. Shown are mean percentages that arise 
from pooled percent control values calculated from duplicate readings of duplicate 
sample wells for independent experiments +/- SEM values for n = 5-7. No statistically 
significant difference exists between insult groups.
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1 Control 230+/-43.3 100
H A 141 +/- 29.0 67 +/-11.7
Control 230 +/- 29.6 100
X/XO 130 +/- 8.7 58 +/- 4.58
7 Control 180 +/-12.3 100
H A 142 +/-12.4 75 +/- 5.78
Control 166 +/. 17.3 100
X/XO 111 +/- 8.4 67 +/- 3.06
Table 8 . Effects of acute challenge on uptake values of ̂ H-D-aspartate in 
BSO (SOOpM) treated astrocytes. BSO was administered with DMEM/F12 w/ 10%
FBS feeding every fourth day in culture. On day of assay astrocytes are removed from 
37°C incubation, media is removed and replaced with assay buffer and insulted with 
X/XO (500jjiM/5mU/ml FV) or H2 O2  (50|xM FV), incubated at 37°C for 15 minutes. 
Uptake values in presence of 25 pM ^H-D-aspartate measured over 5 min at 30°C. Shown 
are mean percentages that arise from pooled percent control values calculated from 
duplicate readings of duplicate sample wells for independent experiments +/- SEM values 
for n = 5-7. No statistically significant difference exists between insult groups
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Figure 14. Summary of uptake values of ̂ H-D-aspartate in untreated and BSO 
(SOOpM) treated astrocytes following acute oxidant exposure. BSO was administered 
with DMEM/F12 w/ 10% PBS feeding every fourth day in culture. On day of assay 
astrocytes are removed from 37°C incubation, media is removed and replaced with assay 
buffer and insulted with X/XO (SOOpM/SmU/ml FV) or H2 O2  (50pM FV), incubated at 
37®C for 15 minutes. Uptake values in presence of 25 pM ^H-D-aspartate measured over 
5 min at 30°C. Shown are mean percentages that arise from pooled percent control values 
calculated from duplicate readings of duplicate sample wells for independent experiments 
+/- SEM values for n = 5-7. No statistically significant difference exists between insult 
groups.
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Figure 15. Tryptophan fluorescence in BSO (SOOpM) treated astrocytes. BSO was
administered with DMEM/F12 w/ 10% FBS feeding every fourth day in culture. 
Following protein determination, equivalent amounts of protein were centrifuged on a 
high-speed microfuge, resuspended in 1% SDS, re-homogenized, and relative 
fluorescence determined at ex 280X em 345X. Shown are mean values of percent of 
controls for multiple readings from individual experiments expressed as % RFU +/- SEM 
for n = 3-5. No statistically significant difference exists between groups.
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Figure 16. Tryptophan fluorescence in acutely challenged untreated astrocytes.
Astrocytes are exposed to either X/XO (500p,M/5mU/ml FV) or H2 O2  (50pM FV) at 22- 
29 days old (day 1 and 7 post-plating) and allowed to incubate at 37°C for 15 minutes as 
in uptake experiments. Following protein determination, equivalent amounts of protein 
were centrifuged on a high-speed microfuge, resuspended in 1% SDS, re-homogenized, 
and relative fluorescence determined at ex 280X and max em (405-410k). Shown are 
mean values of percent of controls for multiple readings from individual experiments 
expressed in RFU +/- SEM for n = 4. No significant difference exists between groups.
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Figure 17. Tryptophan fluorescence In acutely challenged and BSO (SOOpM) treated 
astrocytes. Astrocytes are exposed to either X/XO (500pM/5mlJ/ml FV) or H2 O2  (SO îM 
FV) at 22-29 days old (day 1 and 7 post-plating) and allowed to incubate at 37®C for 15 
minutes as in uptake experiments. Following protein determination, equivalent amounts 
of protein were centrifuged on a high-speed microfuge, resuspended in 1% SDS, re­
homogenized, and relative fluorescence determined at ex 280X and max em (405-410k). 
Shown are mean values of percent of controls for multiple readings from individual 
experiments expressed in RFU +/- SEM for n = 4. No statistically significant difference 
exists between groups.
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Figure 18. Tryptophan fluorescence summary in untreated and BSO (SOOpM) 
treated astrocytes exposed to an acute oxidant challenge. Astrocytes (BSO treated or 
im-treated) are exposed to either X/XO (500pM/5mU/ml FV) or H 2 O2  (50pM FV) at 22- 
29 days old (day 1 and 7 post-plating) and allowed to incubate at 37°C for 15 minutes as 
in uptake experiments. Shown are mean values of percent of controls for multiple 
readings from individual experiments expressed as % RFU +/- SEM for n = 6. No 
statistically significant difference exists between groups.
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Discussion
The uptake of glutamate through the glutamate transporters is the only known mechanism 
(aside from diffusion) for clearing glutamate from the synaptic space. The present study 
was undertaken to examine the sensitivity of glutamate transport to mild oxidative stress 
induced as a consequence of glutathione depletion. Central to this project are two 
fundamental observations. The first is that glutamate transporters provide a link between 
excitotoxicity and ROS production. Excessive oxidative stress has been shown to inhibit 
glutamate transport by direct action on the transporters (Piani et al., 1993; Volterra et al., 
1994; Trotti et al., 1997; Rao et al., 2003). Following transport inhibition, extracellular 
glutamate levels increase and can accumulate to excitotoxic levels. Excitotoxic levels of 
glutamate, through a calcium dependent manner, can lead to ROS production (Dugan et 
al., 1995; Reynolds et al., 1995; Lancelot et al., 1998; Rao et al., 2003). A common 
approach to study the relationship between excitotoxicity and oxidative damage has been 
to introduce oxidants at levels high enough to induce excitotoxicity and death in glia and 
neurons.
In contrast, we chose to examine the effects of endogenously produced oxidative 
stress on glutamate transport. Because the majority of glutamate transport is thought to be 
mediated by glial cells, astrocytes were chosen as our experimental system. Under the 
conditions employed, primary astrocytes expressed the GLAST subtype of glutamate 
transporters. All of the glutamate transporters examined (GLAST, GLT-1, EAACl) have 
been reported to be equally susceptible to ROS-mediated inactivation as a result of 
oxidation of conserved cysteine residues (Trotti et al., 1997; Trotti et al., 1998). The
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conversion of cysteine residues from the reduced to the oxidized state is thought to 
influence the Vmax of transport, but not the apparent affinity for substrate (Km).
The second observation is that glutathione serves as a significant cellular 
antioxidant and reducing agent (Orlowski et al., 1976; Raps et al., 1989; Meister, 1995; 
Ben-Yoseph et al., 1996). In studies by Volterra et al the application of 500pM/50mU/ml 
X/XO and 500pM H2 O2  to astrocytes resulted in the inhibition of glutamate uptake that 
was prevented and partially restored with GSH and the disulphide reducing agent DTT. 
Interestingly, the transport activity could not be prevented or restored with lipophilic 
antioxidants (vitamin E, lipophilic iron chelators, MP) nor were any lipid peroxidation 
products present (Volterra et al., 1994). For this reason, we hypothesized that the 
glutamate transporter proteins may rely on GSH for protection from oxidative damage.
In the CNS, glial cells are thought to be a major source of GSH synthesis. The 
primary astrocytes used for this study contained stable levels of GSH throughout the 
experimental time course. To assess the sensitivity of the glutamate transporters to 
endogenous levels of ROS produced through normal cellular metabolism, intracellular 
GSH levels were depleted with BSO and the uptake of D-aspartate was measured. Initial 
studies confirmed both the effectiveness of BSO as an inhibitor of GSH synthesis and the 
lack of a substantial experimental introduction of exogenous GSH in the astrocyte 
cultures (see Results). The potential sensitivity of transport activity was then further 
examined by exposing cells to non-lethal levels of well known exogenous oxidants. The 
ability to attenuate transport through the EAATs through relatively high levels of ROS 
exposure has been demonstrated (Piani et al., 1993; Volterra et al., 1994; Trotti et al., 
1997; Rao et al., 2003). It was hypothesized that if the EAATs were insensitive to
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oxidative inactivation by GSH depletion alone, that the transporters may exhibit an 
increased vulnerability to exogenous oxidants. While the LD50 for depends on 
many factors including cell type, length of exposure, transition metals present, media 
constituents, the amount of H2 O2  employed in this study was substantially lower than that 
shown to induce cell death and is referred to as sub-lethal or moderate. Initial values were 
chosen that previously demonstrated measurable effects on uptake (^^80% of control) in 
similar cultures in our lab (Webster, 1998). Experiments with astrocytes indicate that 
oxidant levels as high as 500pM H2O2  and 500pM/50mU/ml X/XO are capable of 
inhibiting glutamate uptake without demonstrating a significant release of LDH (Volterra 
et al., 1994). The assumption was made, based on this information, that moderate insult 
would be achieved with 50pM H2O2  and 500pM/5mU/ml X/XO. Interestingly, as far as 
H2 O2  is concerned, the value used in our experiments approximates that which could be 
measured in freshly voided human urine (Halliwell, 2000). In the present experiments, 
cells were washed prior to adding oxidants so that any GSH in the cell media of untreated 
cells would be removed in this step. Therefore, upon addition of the assay buffer and 
oxidant, the extracellular conditions of the untreated astrocytes and those treated with 
BSO were identical.
Oxidative insults far exceeding those used in this study have previously been 
shown to inhibit uptake, and is primarily thought to be due to protein damage (Volterra et 
al., 1994; Drukarch et al., 1997; Trotti et al., 1997). The fluorescence of tryptophan 
residues are commonly used to monitor changes in protein structure (Jang et al., 1989; 
Kleinschmidt et al., 1999; Ladokhin et al., 2000; Hansen et al., 2002; Mozo-Villarias,
2002). The changes in proteins following exposure to oxidants are significant enough to
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elicit declines in tryptophan fluorescence (Davies et al., 1987; Jones et al., 1987; LeBel et 
al., 1991). It has been shown that the pyrrol ring of tryptophan is the most susceptible to 
oxidative attack resulting in the formation of a number of degradation products (Simat et 
al., 1998). While tryptophan degradation and the concurrent change in fluorescence is not 
an exclusive phenomena in terms of protein oxidation, it does serve as an established 
indicator for insult studies (Davies et al., 1987).
We found that decreasing intracellular GSH levels does not affect the uptake rates of D- 
aspartate through GLAST. This suggests that ROS produced endogenously during normal 
respiration in the primary astrocytes do not accumulate to a level that are deleterious to 
the transport process under conditions of GSH depletion. This could mean that under the 
conditions used, the metabolic rate of astrocytes may not have been sufficient to generate 
a level of ROS capable of altering the transport process. It is possible that certain energy 
dependent processes in astrocytes (glutamate uptake, glutamine synthesis, and 
glutathione synthesis) may be limited in the present study due to both the low level of 
glutamate in the media (50 pM) and the presence of BSO. Therefore, as a consequence of 
a lowered metabolic rate, endogenous ROS generation may be diminished.
Alternatively, it is also possible that the cells are generating toxic levels of ROS 
endogenously but are protected through mechanisms other than GSH. It has been shown 
that removing the scavenging capacity of GSH does not always lead to pathology or cell 
death. For example, acatalasaemia, the deletion of GSH-peroxidase, appears to produce 
no specific phenotype (Halliwell, 2000). Therefore, it would not be surprising if 
astrocytes were capable of compensating for lowered GSH levels and oxidative stress. In
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fact, when astrocytes are treated with 500^M BSO, GSH levels are lowered (10% of 
control) but no accumulation of NO* or H2 O2  is observed (McNaught et al., 2000). Not 
only do astrocytes appear to be under a low amount of stress during GSH depletion, but 
when treated with various amounts of H2 O2  under normal conditions they are shown to 
exhibit as much as a 6-fold higher resistance to cell death than neurons (Ben-Yoseph et 
al., 1996). These observations may be explained in part by the up-regulation of the 
pentose phosphate pathway in astrocytes verses neurons (Ben-Yoseph et al., 1996) as 
well as antioxidant enzyme upregulation (MnSOD, GPx, catalase) that in some cases is 
known to occur in cells exposed to various levels of oxidative stress (Rohrdanz, 2001).
Another possibility is that the activity of the glutamate transporters is not sensitive 
to oxidative insult as initially thought. This does not appear to be the case, however, as 
transport activity was inhibited by moderate levels of exogenously applied oxidants 
(50pM H2 O2 and 500pM/5mU/ml X/XO). When astrocytes were depleted of GSH and 
treated with the same oxidative challenge, transport was not further attenuated. This 
means that even when oxidant levels capable of altering transport are applied to 
astrocytes, depleting intracellular GSH levels does not increase the vulnerability of the 
glutamate transporters.
Taken together these results suggest that under the conditions stated, the 
availability of GSH is not likely important for the protection of the transporters from 
endogenously produced or exogenously administered oxidants. Similar results have been 
observed by others (Piani et al., 1993). One explanation is that the ability of GSH to 
scavenge free radicals and reduce thiol groups may be limited depending on the 
predominant site of oxidative damage (intracellular or extracellular). The effect of the
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oxidants then must be considered in terms of oxidatively vulnerable sites on the 
transporter proteins. To address the susceptibility of GLAST, we must consider both the 
direct and indirect modifications that could result from ROS treatment. A change in 
protein structure and possibly function can result from the direct oxidation of proteins 
from ROS and lipid-propagated peroxidation. Additionally, changes in membrane 
integrity and essential cellular proteins can indirectly modify the function of the 
glutamate transporters.
The most direct form of damage would be to the transport protein itself, through 
the modification of primary structure accomplished via a variety of amino acid 
alterations. The highly specific and selective nature of proteins can be compromised 
greatly by seemingly minor changes in amino acid moieties. Changes in protein 
conformation, folding, and subsequently, function, can result from ROS damage to amino 
acids. One of the most common examples of this is the oxidation of sulfhydryl groups on 
cysteine residues resulting in disulphide bond formation. Three of the glutamate 
transporter subtypes (GLAST, GLT-1, EAACl) have been shown to be equally inhibited 
by the direct action of oxidants and despite the number of cysteine moieties contained in 
each subtype (three in GLAST (Storck et al., 1992), nine in GLTl(Pines et al., 1992), and 
six in EAACl(Kanai et al., 1992)) it is believed that they share a common regulatory 
mechanism governed by the chemical redox state of cysteine groups (Trotti et al., 1997; 
Trotti et al., 1998 for review). And because two conserved cysteine groups exist between 
all glutamate transporters, this very well could be the most significant susceptible site for 
direct effects on function.
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In GLAST, C l86 and C375 are the conserved cysteine residues (accession 
numbers: GLAST, P24942; GLT-1, P31596; EAACl, P31597). According to the current 
consensus on glutamate transporter topology, at least three extracellular loops exist and 
may contain redox sensitive target sites (for review see Danbolt, 2001). Interestingly, 
C186 (Wahle et al., 1996) and C375 (Seal et al„ 2000) in GLAST are both thought to be 
located extracellularly. This information may help to explain why GLAST transport 
activity in untreated cells (containing 6-fold more intracellular GSH content than BSO- 
treated cells) and those treated with BSO was equally affected by the introduction of 
oxidants. It is possible that the hydrogen peroxide and products xanthine/xanthine 
oxidase reaction had access to extracellular cysteine groups and intracellular GSH is not 
exported from the untreated cells in sufficient amounts to protect this portion of the 
transporter. Even though the membrane permeability of the oxidants would grant them 
access to the intracellular space, as long as the sites of vulnerability of GLAST are 
extracellular, it is possible that intracellular protectant mechanisms are not relevant. 
Additionally, unlike the cultures chronically depleted of GSH, it is not likely that 
astrocytes exposed to oxidants for 15-minutes are capable of opposing the insult through 
upregulation of various antioxidant enzymes (Piani et al., 1993).
Extracellular oxidation of cysteine groups on GLAST is one but not the only 
mechanism whereby transport may be compromised following exposure to oxidants. 
Direct modifications to the membrane or transporter-dependent proteins may indirectly 
affect the activity of the transporters. Membrane damage from lipid peroxidation 
involves hydroxy radical initiation of the self-propagating chain whereby the abstraction 
of a hydrogen atom from a polyunsaturated fatty acid side chain forms carbon centered
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lipid radicals. Carbon centered radicals most likely react with in vivo to form peroxyl 
radicals which interact with nearby lipids to form more lipid radicals, peroxyl radicals, 
lipid hydroperoxides, and reactive aldehydes, propagating the oxidative chain (Halliwell, 
1992). Additionally, in the presence of transition metal ions, hydroperoxides can generate 
lipid peroxyls and the chain can continue. Membrane proteins can be damaged directly 
by the products of the lipid peroxidation chain (peroxyl radicals and aldehydes) or 
indirectly through changes in membrane fluidity, altered permeability of the membrane to 
ions, and decreased ATPase function as a result of increased oxidation of membrane 
lipids (Halliwell, 1992; Juurlink et al., 1998). Undoubtedly, a change in Na^, K ,̂ and H  ̂
permeability can disrupt the electrochemical gradients that are responsible for the 
transport of glutamate, and lowered ATP levels can precipitate gradient failure. 
Maintaining a glutamate gradient of several thousand-fold is highly energy dependent as 
can be seen in episodes of ischemia where oxygen and ATP levels are diminished and 
neuron cell death occurs. An energy coupled ionic gradient is not the only requirement 
for transport, however, thermodynamically uncoupled ion gradients, pH changes (lower 
inside and higher outside), as well as temperature all affect the transport process 
(Danbolt, 2(X)1 for review).
Membrane disruption through lipid peroxidation is clearly a deleterious process to 
glutamate transport. However, lipid peroxidation is unlikely to occur independently of 
protein damage, but protein damage has been shown to occur independently of lipid 
damage (Volterra et al., 1994). Therefore, in addition to direct protein damage of the 
transporters, there could exist situations where direct damage to adjacent or functionally 
dependent proteins indirectly alters glutamate transport activity. For instance, there is
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accumulating evidence that the glutamate transporters, similar to other membrane 
transporter and receptors, may be kept in place by anchoring proteins. These proteins are 
shown to bind to the C-terminal ends of the transporters (intracellularly) and serve to 
maintain the specialized localization of the transporters and possibly play a role in 
transporter trafficking. The intracellular C-terminus of EAATS has a protein binding 
motif similar to a binding domain on NMDA receptors, GLAST has a C-terminal binding 
site that modulates its affinity for glutamate, and the C-terminal of GLT-1 is an oxidation 
site mediated by mutant superoxide dismutase (Danbolt, 2001). Therefore, transporter 
expression and activity could be compromised through the alteration of associated 
proteins.
Speculation upon the source of oxidative stress is limited to the technique used to qualify 
the resultant damage. Because ROS are normally reactive and labile, it is often difficult to 
measure them directly. The direct oxidation of proteins, however, can modify the 
ultraviolet spectrum and fluorescence of protein, or more often, render it more reactive 
with certain compounds that can subsequently be assayed. In this way, more stabile 
oxidatively modified products of proteins and lipids are measured as markers of oxidative 
damage. Protein carbonylation (Levine, 1990; Chevion, 2000), oxidation products of 
tryptophan, histidine, lysine, methionine, and phenylalanine (Simat et al., 1998; Chevion, 
2000), lipid peroxides (Gotz, 1993; Shwaery, 1999), 4-hydroxynonenol (Rohn et al., 
1998), and oxidant-sensing fluorescent probes (Hempel, 1999) serve as reliable markers 
of oxidative stress. In the results presented above, tryptophan fluorescence did not change
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relative to the decline in intracellular GSH over the 28-day course, as well as to mild 
acute challenge in both untreated and BSO-treated astrocytes.
The results of the tryptophan fluorescence experiments indicate that tryptophan 
oxidation did not occur to a significant degree in astrocyte proteins exposed to a mild 
oxidative insult, proving the null hypothesis. This assumes that the amounts of HjOj and 
X/XO applied to astrocytes were unable to oxidize tryptophan moieties that face 
extracellularly, did not gain access to the intracellular environment, or if they did, were 
insufficient for measurable oxidative damage. Concentration is not the only condition that 
may explain the outcome however. The additions of H2O2  were allowed to incubate at 
3TC  for 15 minutes, this may not have been long enough to see changes in the cellular 
proteins. Simat et al has shown that temperature and an extended time course of up to 6 
hours are determinants for measuring a loss tryptophan fluorescence in peptides and 
proteins exposed to 0.2M H2 O2  (Simat et al., 1998).
The contribution of antioxidants other than GSH toward ROS scavenging may 
have limited the oxidative stress that cells were under and consequently diminished any 
measurable protein fluorescence. Cu,Zn-SOD and Mn-SOD may serve as additional 
enzymatic systems for combating extra free radicals produced during respiration in the 
absence of GSH. The product of SOD, HgOg remains a possible mediator of protein 
damage and absence of GSH prevents glutathione peroxidase from facilitating its 
removal. However, other peroxidases in the brain exist, and thioredoxin-dependent 
peroxidases have been linked to preventing ischemic oxidative damage and cell death 
(Halliwell, 2001). Intracellularly, glia and neurons concentrate ascorbate to millimolar 
levels and this too may render mild oxidative insult (assuming it gets in) ineffective.
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Lipid protection is often thought to be mediated through a-tocopherol, and while 
important for quenching lipid peroxidation chain events, its role is not fully understood as 
normal levels in the CNS are not linked with a preventative effect on aging, Alzheimer’s, 
or Parkinson’s disease (Halliwell, 2001). In this study, the normal production of GSH 
through functional transport of glutamate and cystine serves as the major peroxide 
scavenging reductant in the samples not treated with BSO.
This does not imply however, that in the absence of observed changes in 
tryptophan fluorescence, the incubation time or concentration was insufficient, or that the 
cellular environment was sufficiently protective. It is likely that some constituents within 
the insult regimen serve to limit the oxidation of tryptophan. In experiments where cells 
were treated with the free radical generating system X/XO, uric acid with the concurrent 
generation of one H2 O2  molecule and one superoxide ion are produced. Uric acid as well 
as the main constituent of the assay buffer, HEPES, are both known to protect against 
tryptophan loss in studies with free radical insult to BSA (Davies et al., 1987). Just 
because the insult applied may be insufficient to cause oxidation of tryptophan residues 
or is undetectable for some other reason, it does not mean that inhibition of D-aspartate 
uptake in cells exposed to ROS is not the result of oxidative damage. As mentioned 
earlier, there are other markers of oxidative damage other than tryptophan fluorescence 
and these may better reveal the modifications that may have occurred to GLAST or other 
cellular proteins. In other words, protein damage likely occurred from H2 O2  and X/XO 
treatment, however, the nature of the protein damage may be more sensitive or more 
specific than the technique used to resolve it. In this study, it appears D-aspartate uptake 
served as a more sensitive marker of oxidative stress than did tryptophan fluorescence.
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Conclusion
The effects (direct and indirect) of the oxidants responsible for the decline in GLAST 
activity, appear to be independent of intracellular GSH levels. We conclude that the 
availability of GSH is probably not important for the protection of GLAST from 
endogenously produced or limited levels of exogenously administered oxidants because 
of the rate of ROS normally generated in cultured astrocytes, alternative compensatory 
mechanisms, or the inability of intracellular GSH to sufficiently protect the extracellular 
portion of the transporter from oxidative stress. It is likely that the protecting ability of 
GSH is dependent on where (intracellular or extracellular) the oxidants predominantly 
exert their effects. Sulfhydryl groups on the extracellular surface of GLAST may be 
inaccessible to intracellular GSH and thus be the most susceptible sites for oxidation 
following H2O2  and X/XO exposure. Because the decline in D-aspartate transport activity 
associated with untreated and BSO-treated astrocytes was not paralleled by tryptophan 
fluorescence, it appears that in this case transport activity served as a more reliable 
marker of oxidative stress than the more general marker.
The production of ROS and oxidative inactivation of the glutamate transporters 
have been associated with a number of neuropathologies. Consequently, a major strategy 
for the treatment of acute pathology and neurodegeneration has involved using 
antioxidant therapies to both increase protective enzymes and suppress oxidative stress. 
One interpretation of the current results may be that the antioxidant GSH is not a relevant 
therapeutic target for the protection of the transporters and their downstream links to 
excitotoxicity.
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However, the often multifactorial nature of disease progression limits the validity 
of this conclusion. For any one disease state there may exist a number of possible risk 
factors that can independently lead to an identical pathology. Genetic polymorphisms in 
repair mechanisms, mitochondrial enzymes, and DNA repair mechanisms may have 
similar clinical manifestations but require very different therapies. For example, patients 
afflicted with ALS have responded to some antioxidant therapies and not others, while 
current research suggests that oxidative stress may not play a significant role in the 
etiology of the disease (Halliwell, 2001; Tortarolo et al., 2004). Additionally, the inability 
to separate cause from consequence in pathology further confounds the treatment process. 
One consequence in those afflicted with Parkinson’s disease is lowered GSH levels. 
However, decreasing GSH levels does not reproduce Parkinson’s disease (Danbolt, 2001; 
Halliwell, 2001). It is likely that the results of a focused study are better applied to a 
growing body of knowledge relating to a particular disease state than directly to a 
treatment paradigm.
The relevance of GSH in therapy remains unknown. Clearly, protecting the 
transporters from oxidative inactivation may limit the excitotoxicity cascade (Figure 5). 
Therefore, continued investigation of transport sensitivity to oxidative stress is required.
A number of factors could influence the response of transport activity to oxidative stress, 
including the amount of ROS used, the time course of exposure (acute verses chronic), 
and the site of exposure. While previous studies have focused on acute exposure to high 
levels of ROS at a number of sites in the CNS, we chose to study chronic exposure to low 
levels of ROS, in one cell type. In order to better understand the dependence of glial 
transport on GSH, the role of neurons must be considered. In a co-culture system
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consisting of astrocytes and neurons, the metabolic rate of astrocytes may increase as a 
result of enhanced growth and activity, leading to higher levels of ROS, and consequently 
increase the reliance of astrocytes on the antioxidant qualities of GSH. This effect would 
be compounded by the high energy demands of neurons (transport, synthesis, storage, 
release) which may lead to increased endogenous oxidative stress and result in even 
higher rates of GSH turnover in the co-culture system. To ascertain the role of GSH in 
this co-culture scenario it would be advantageous to not only observe the effects of 
depletion but also to use GSH to prevent or recover any effects on transport that may 
occur. Depending on the reducing reagents used, this may also address the location of the 
damage that may occur from endogenous oxidative stress to the transporters. As 
mentioned above, there also is the possibility that mechanisms other than GSH may serve 
to compensate for oxidative stress in astrocytes. In vivo and in vitro observations indicate 
that neurons are more susceptible to excitotoxicity and ROS than astrocytes and undergo 
cell death earlier and in higher numbers (Ciani et al., 1996; Magistretti, 2003; Rao et al.,
2003). Neuronal morbidity could be used to help assign priorities to various protectant 
mechanisms under investigation.
Glutamate transport is thought to regulate the interaction of two destructive 
processes: excitotoxicity and ROS formation. Further insight into the sensitivity of the 
transporters to ROS-mediated damage is necessary for understanding pathogenic events 
resulting from aberrant glutamate neurotransmission.
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